US.PFE · Pfizer

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 1.9217448577507539,
        "turnoverUsdM": 884.803949464,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1.2
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.PFE",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 28.8758,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2.5,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 3.8,
      "take_profit_price": 31.5315,
      "target_multiplier": 1.9,
      "technical_strength": 1.83,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.3009011003292323,
    "stopLossPercent": 3.8434897155015078,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 64.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 57.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 28.787,
    "ma50": 28.2952,
    "close": 30.03,
    "prevClose": 30.42,
    "avgVolume20": 29762155,
    "volumeRatio": 0.99,
    "changePercent": -1.28
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.015213015551047926,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.9928322592308482,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.9195931271108699,
      "volat_points": 0,
      "day_range_pct": 0.016983016417482025,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 64.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 52,
        "contribution": 2.6
      },
      {
        "raw": 14.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 74,
        "contribution": 14.8
      },
      {
        "raw": 5.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 37.33,
        "contribution": 5.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 22.2,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 74,
        "contribution": 22.2
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 57.8,
    "details": [
      "基本面分析總分: 2.6/5分",
      "資金流分析總分: 14.8/20分",
      "市場環境分析總分: 5.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 22.2/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.6,
      "資金流": 14.8,
      "市場環境": 5.6,
      "情緒分析": 3,
      "技術信號": 22.2,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 884.803949464,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.5,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 3.2,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.PFE",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 735.23500335,
                "ma50": 725.8121993399999,
                "name": "QQQ",
                "close": 704.40002,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.1504974000001,
                "ma50": 767.8083956999998,
                "name": "SPY",
                "close": 759.96997,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 1.9217448577507539,
          "atrPoints": 4,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143142713,
                "url": "https://finnhub.io/api/news?id=920e6f43b92259a07b5f4b48ee34d763d2c1a24f5e37a5c533d1c69621bf98c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) is back in focus after signing a research collaboration and license agreement with Enodia Therapeutics that gives the drugmaker access to Enodia’s Sec61 inhibitor programs for potential oncology and specialty treatments. Pfizer’s agreement with Enodia lands at a time when momentum in the shares has been rebuilding, with a 30 day share price return of 6.56% and a 90 day gain of 22.37%. The 1 year total shareholder return of 29.79% contrasts with a weaker 5 year total shareholder...",
                "category": "company",
                "datetime": 1792800893,
                "headline": "Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes?"
              },
              {
                "id": 143165539,
                "url": "https://finnhub.io/api/news?id=cf66cd34f14be1922ec528f48ae5f7caca4ba44846743a21e68ea79126a0a36c",
                "image": "https://image.cnbcfm.com/api/v1/image/108448873-17927067361792706735-49169855386-1080pnbcnews.jpg?v=1792706736&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.",
                "category": "company",
                "datetime": 1792692690,
                "headline": "Fast Money: PFE, GOOGN, CAPRI, AMT"
              },
              {
                "id": 143081308,
                "url": "https://finnhub.io/api/news?id=8ce09ca18fb771b068a5c289e547d25a9ec2ac820b90b0c25c7e6e22f610346e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) signed a new research collaboration and license agreement with Enodia Therapeutics to develop Sec61 inhibitors. The arrangement centers on small-molecule Sec61 blockers that Enodia is advancing using its proprietary discovery platform. Under the alliance, Pfizer gains rights to discover, develop and potentially commercialize drug candidates that emerge from Enodia's Sec61 programs. This Sec61-focused collaboration with Enodia is an important piece to weigh against the rest...",
                "category": "company",
                "datetime": 1792643436,
                "headline": "Pfizer (PFE) Signs New Drug Discovery Pact Focused On Sec61 Inhibitors"
              },
              {
                "id": 143032216,
                "url": "https://finnhub.io/api/news?id=5c554f19368c85befd37cd10c9178598e9f34ce0b2fce123c581d489d25d19b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In the latest trading session, Pfizer (PFE) closed at $30.11, marking a +2.28% move from the previous day.",
                "category": "company",
                "datetime": 1792529105,
                "headline": "Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing"
              },
              {
                "id": 143025927,
                "url": "https://finnhub.io/api/news?id=6571c3c98b4a4708822b6076548fb51d5da07a62e9517d2f0621dfd89a165832",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1792497604,
                "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 142930843,
                "url": "https://finnhub.io/api/news?id=429e2a1fa563a7d185d0ec9fa4b1c6774eefa25140f82a3a32e8ccc8285c7ebd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer recently secured expanded FDA approval for TUKYSA as a chemotherapy free maintenance option in HER2 positive metastatic breast cancer and reported a wide slate of infectious disease vaccine data, including late stage Lyme, pneumococcal and RSV studies. The breadth of vaccine and oncology updates points to Pfizer leaning heavily on late stage pipelines and real world evidence to support future portfolio mix as older products face patent expiry and COVID sales pressure. We will now look...",
                "category": "company",
                "datetime": 1792125052,
                "headline": "Tukysa Approval Might Change The Case For Investing In Pfizer Stock (PFE)"
              },
              {
                "id": 142896564,
                "url": "https://finnhub.io/api/news?id=704fe4e236b4403de7ca0be3343215911cb4c95daf902cf7ffa7f7d6cd6fa5aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Insider purchases, a multibillion-dollar acquisition and progress in vaccine research helped drive interest.",
                "category": "company",
                "datetime": 1792036063,
                "headline": "Why Did GME, BMBL, PFE Stocks Hit 52-Week Highs Today?"
              },
              {
                "id": 142888488,
                "url": "https://finnhub.io/api/news?id=30968c24443e8adac169e6499d5170bb4ec0b066c47f0edd1601090ab47ea410",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The latest trading day saw Pfizer (PFE) settling at $29.21, representing a +2.96% change from its previous close.",
                "category": "company",
                "datetime": 1792010705,
                "headline": "Pfizer (PFE) Gains As Market Dips: What You Should Know"
              }
            ],
            "raw_source": [
              {
                "id": 143181249,
                "url": "https://finnhub.io/api/news?id=310ee1c3da03605918a65c5e2ab945f7ee58ce597d31d3f5ff8e6cfd75092f4b",
                "image": "",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1792926913,
                "headline": "Buy 8 Barron's Big Better Bets (Than T-Bills) Out Of 14 'Safer' October DiviDogs"
              },
              {
                "id": 143168789,
                "url": "https://finnhub.io/api/news?id=5879be54ec187cc6861d2f250a3a13733d6b1037c3ff06004c8211877b000cab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Warning signs around heavily indebted AI infrastructure firms have grown louder after analysts raised the risk of a tech debt spiral, with some newer players struggling to finance data centers and high-end chips. That strain shifts attention toward more grounded uses of AI that address urgent problems such as healthcare. Investors seeking substance over hype may find this article useful. It profiles three AI powered healthcare stocks from our screener. The three stocks covered below are a...",
                "category": "company",
                "datetime": 1792879784,
                "headline": "Pfizer And 2 Other AI Healthcare Stocks To Watch"
              },
              {
                "id": 143164916,
                "url": "https://finnhub.io/api/news?id=70c8a66ac8547e7b5ea9a78af63b41907d20032ab85d24bdbd832413628bc66f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, October 24, 2026--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today",
                "category": "company",
                "datetime": 1792855080,
                "headline": "Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026"
              },
              {
                "id": 143163697,
                "url": "https://finnhub.io/api/news?id=11681aa2bf1416e76d07fafb28671f83c20941adfaaa8a6a644c07fe1b246b9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A flashy dividend yield can mask serious cracks in a company's finances, and four well-known names are showing the same warning signs that preceded Whirlpool's sudden payout suspension earlier this year.",
                "category": "company",
                "datetime": 1792850444,
                "headline": "4 High-Yield Dividends That Could Be Next on the Chopping Block"
              },
              {
                "id": 143151905,
                "url": "https://finnhub.io/api/news?id=23d1e292c44b1cd3e82ecf62aaa1ddc93cc30e22dad7bf4bec556aea1cf9eb83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer has a plan to bounce back from recent obstacles.",
                "category": "company",
                "datetime": 1792826400,
                "headline": "Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem"
              },
              {
                "id": 143142713,
                "url": "https://finnhub.io/api/news?id=920e6f43b92259a07b5f4b48ee34d763d2c1a24f5e37a5c533d1c69621bf98c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) is back in focus after signing a research collaboration and license agreement with Enodia Therapeutics that gives the drugmaker access to Enodia’s Sec61 inhibitor programs for potential oncology and specialty treatments. Pfizer’s agreement with Enodia lands at a time when momentum in the shares has been rebuilding, with a 30 day share price return of 6.56% and a 90 day gain of 22.37%. The 1 year total shareholder return of 29.79% contrasts with a weaker 5 year total shareholder...",
                "category": "company",
                "datetime": 1792800893,
                "headline": "Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes?"
              },
              {
                "id": 143133429,
                "url": "https://finnhub.io/api/news?id=5951d905afce950044c9d6e2bfe16ba48e29264a08468d6e9fd7f0eddd417f3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding after an 18% collapse. The selloff raises a pointed question about whether the data actually delivered what investors spent months betting on.",
                "category": "company",
                "datetime": 1792761473,
                "headline": "Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip"
              },
              {
                "id": 143161698,
                "url": "https://finnhub.io/api/news?id=53b990e2048d7e7733dfa3e1a181d1e1577ec4db3f25cb142d68d0c34ca94e0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.",
                "category": "company",
                "datetime": 1792754700,
                "headline": "3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach"
              },
              {
                "id": 143129947,
                "url": "https://finnhub.io/api/news?id=dd1033de1a38808c96bfaf9f76cf0ea22287ed9a1757cd789080f8438e109cdc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792750443,
                "headline": "What Sent Eli Lilly Stock Higher Over The Past Year?"
              },
              {
                "id": 143128610,
                "url": "https://finnhub.io/api/news?id=89bb022e7ab98f8052a1d6c38dc5e4b4964e2313b38108adc120835b2eb6384a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "One of these pharma stocks offers more income, but the other offers a safer dividend.",
                "category": "company",
                "datetime": 1792749780,
                "headline": "Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?"
              },
              {
                "id": 143133158,
                "url": "https://finnhub.io/api/news?id=a3ad2c261e7cd95079654eec83b72e8def0cacd0aa86972a4ea01ff84be76950",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/23/Healthcare-stocks.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Analysts highlight high-yield healthcare stocks Perrigo (7.09%), Pfizer (5.65%) and CVS Health (2.82%), with updated ratings and news.",
                "category": "company",
                "datetime": 1792744209,
                "headline": "Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields"
              },
              {
                "id": 143127363,
                "url": "https://finnhub.io/api/news?id=52ebefcc082f0a8690bbd83d4907a06b9e6deaa848edcb7c19c8ff8c18f7526e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The prohibitions could cut off Big Pharma from Chinese biotechs—the source of many promising cancer treatments",
                "category": "company",
                "datetime": 1792742940,
                "headline": "U.S. Treasury Wants to Rein In Deals for Chinese Biotech and AI"
              },
              {
                "id": 143124377,
                "url": "https://finnhub.io/api/news?id=35a567ab400cc509afa96f335189f8350dc665d14e7053e42fbeb4de7d7c049c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792742436,
                "headline": "How Much Downside Is Left In Moderna Stock?"
              },
              {
                "id": 143106842,
                "url": "https://finnhub.io/api/news?id=e1cb5a25981342f9c599c8bdabc79af4d8976b99945110614b8bd9900fca9fee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "They definitely matter... up to a point.",
                "category": "company",
                "datetime": 1792714800,
                "headline": "What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer"
              },
              {
                "id": 143104164,
                "url": "https://finnhub.io/api/news?id=ea32a4ec54dc87d8212ecc8cdc5a4e2b36a8e96653548a45a9892cfc01a7fb0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.",
                "category": "company",
                "datetime": 1792705502,
                "headline": "Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue"
              },
              {
                "id": 143165539,
                "url": "https://finnhub.io/api/news?id=cf66cd34f14be1922ec528f48ae5f7caca4ba44846743a21e68ea79126a0a36c",
                "image": "https://image.cnbcfm.com/api/v1/image/108448873-17927067361792706735-49169855386-1080pnbcnews.jpg?v=1792706736&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.",
                "category": "company",
                "datetime": 1792692690,
                "headline": "Fast Money: PFE, GOOGN, CAPRI, AMT"
              },
              {
                "id": 143103258,
                "url": "https://finnhub.io/api/news?id=c35b106a06891790b5b6d1243adde3178b174239f57bf88755c043bb40368202",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven’s experimental spinocerebellar ataxia treatment.",
                "category": "company",
                "datetime": 1792690140,
                "headline": "Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again"
              },
              {
                "id": 143103257,
                "url": "https://finnhub.io/api/news?id=9ef35221a329f1b8f4c7543c256412cadb5862d89c56b71a658f5fcbefbce1e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease medicine spurned by previous FDA leadership.",
                "category": "company",
                "datetime": 1792686240,
                "headline": "Biohaven’s previously rejected rare disease drug to get fresh FDA review"
              },
              {
                "id": 143103177,
                "url": "https://finnhub.io/api/news?id=ffb904d6c2e2e56340e0bfed825ea87d91db362e08f637bf875f9ceda1037aaa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before you chase the bigger payout, the coverage numbers behind each dividend tell a very different story.",
                "category": "company",
                "datetime": 1792685713,
                "headline": "Pfizer’s High Dividend Yield May Be a Warning. Here’s How Merck Compares"
              },
              {
                "id": 143103256,
                "url": "https://finnhub.io/api/news?id=2c033c1f08ca6bdc947ea5869d8e0b67e22589f9750391cb0c68c06de107dcf9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "For income‑focused investors, covered calls can offer an additional way to improve the dividend yield on a stock like Pfizer.",
                "category": "company",
                "datetime": 1792684645,
                "headline": "How To Boost The Dividend Yield On This Drugmaking Behemoth"
              },
              {
                "id": 143100048,
                "url": "https://finnhub.io/api/news?id=2664af14cc6088897231f3cbc67e958e4f4b61005f9bf35b5bd4f94ad44457a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792672351,
                "headline": "Was There Any Sign Merck Stock Would Run?"
              },
              {
                "id": 143100049,
                "url": "https://finnhub.io/api/news?id=f51f2cde69be65003b79d129e719322d83ca9adfc7e4b7bee4deb23441f0c884",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792671368,
                "headline": "Is Johnson & Johnson Stock Ready For A MedTech Stall?"
              },
              {
                "id": 143081308,
                "url": "https://finnhub.io/api/news?id=8ce09ca18fb771b068a5c289e547d25a9ec2ac820b90b0c25c7e6e22f610346e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) signed a new research collaboration and license agreement with Enodia Therapeutics to develop Sec61 inhibitors. The arrangement centers on small-molecule Sec61 blockers that Enodia is advancing using its proprietary discovery platform. Under the alliance, Pfizer gains rights to discover, develop and potentially commercialize drug candidates that emerge from Enodia's Sec61 programs. This Sec61-focused collaboration with Enodia is an important piece to weigh against the rest...",
                "category": "company",
                "datetime": 1792643436,
                "headline": "Pfizer (PFE) Signs New Drug Discovery Pact Focused On Sec61 Inhibitors"
              },
              {
                "id": 143071297,
                "url": "https://finnhub.io/api/news?id=52eab578ffc19c9e3ca9e4df5c44da8f98dac47174e2bd92e488e7e4291514cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792617521,
                "headline": "Are You Overpaying For Regeneron Stock Versus Its Rivals?"
              },
              {
                "id": 143071288,
                "url": "https://finnhub.io/api/news?id=60fab21e4459df56884c06727fb45337dcfb39de578b8bb76a818cb0b9a2c61f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792614371,
                "headline": "Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock?"
              },
              {
                "id": 143070600,
                "url": "https://finnhub.io/api/news?id=41f5226f34db5af377548800478d88791c42319afe872a8b5c18c7788b798c1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792602406,
                "headline": "What Changed In Amgen's Story?"
              },
              {
                "id": 143070007,
                "url": "https://finnhub.io/api/news?id=9776b97d5259c468789e3151b8bb83caac10ccd11f8472847286924cb34501e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Bristol Myers faces mounting generic competition across its legacy portfolio, while Eliquis delivers strong growth and Revlimid shows resilience amid pricing and market pressures.",
                "category": "company",
                "datetime": 1792587600,
                "headline": "Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?"
              },
              {
                "id": 143067523,
                "url": "https://finnhub.io/api/news?id=03483b35f6cf49583b9ddf3394ac484c78167c22c28d16679ca79306f39c9208",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.",
                "category": "company",
                "datetime": 1792585500,
                "headline": "Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?"
              },
              {
                "id": 143054598,
                "url": "https://finnhub.io/api/news?id=495ba275aefeee0a07ee7e5540c293492adc286ab8a63e8e030cefd64ae8034c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "This company made headlines with its coronavirus vaccine.",
                "category": "company",
                "datetime": 1792570920,
                "headline": "Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice"
              },
              {
                "id": 143054599,
                "url": "https://finnhub.io/api/news?id=9c7d43a1e17fcc810631ec1ce8d7b370a37dc1954b135d3fcb999bf5daee505e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- \"Life Science Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The global life science market is experiencing rapid expansion, supported by rising pharmaceutical research and development investment, biotechnology innovation, laboratory automation, and growing demand for advanced diagnostics. The market is projected to increase from $109.53 billion in 2025 to $123.41 billion in 2026, representing a compound annual growth rate of 12",
                "category": "company",
                "datetime": 1792570320,
                "headline": "Global Life Science Market Report 2026: Size, Trends and Forecast to 2030 | Secure $200.6B AI and Precision Medicine Upside with Johnson & Johnson, Roche, Pfizer, and AstraZeneca"
              },
              {
                "id": 143062081,
                "url": "https://finnhub.io/api/news?id=7e1de78f5891215345dfd6d2e5515ee4c53718422c4da052c229550a4da162b6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1355632593/image_1355632593.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Bristol-Myers Squibb yields about 4.3% and trades at 9.1x forward EV/EBIT. Read why BMY stock offers an attractive risk/reward profile.",
                "category": "company",
                "datetime": 1792568710,
                "headline": "Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings"
              },
              {
                "id": 143038886,
                "url": "https://finnhub.io/api/news?id=f9affdbd77d1b4dcc74f6d22d552f857d3ff21a082ed014aac2fd2f3a98ee8b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The dividend is probably the reason investors hold Pfizer (PFE), the maker of medicines such as Eliquis and Padcev. The stock yielded 5.8% at the October 19, 2026 close. Over the past five years, though, the share price has fallen far behind the S&P 500. So take a guess: once every dividend is counted, how did five years of owning Pfizer turn out next to the market.",
                "category": "company",
                "datetime": 1792549586,
                "headline": "What Have Pfizer Stock Holders Really Earned?"
              },
              {
                "id": 143038856,
                "url": "https://finnhub.io/api/news?id=ec360a4c13d51252fc8575917923e9f0301ecea05f1edc0f73085e8b26ff8f30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Shares of Merck (MRK) returned 76.2% over the past year, compared with 17.4% for the S&P 500. U.S. growth for the company's cancer drug Keytruda is set to slow. Management said on the August 4 call that U.S. Keytruda growth will moderate as the drug reaches peak penetration across several key indications. Barron's also reported on October 7 that a Dutch court barred Merck from selling subcutaneous Keytruda in eight European markets. So how much of what Merck sells is Keytruda.",
                "category": "company",
                "datetime": 1792549234,
                "headline": "What Happens To Merck Stock If Keytruda Sales Stop Growing?"
              },
              {
                "id": 143032520,
                "url": "https://finnhub.io/api/news?id=ab1fb432b4e0d266055f3bcc014d0cb49576b503726c50cd73c6dba0592ae40b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "By Karen Roman Slate Medicines, Inc. said Stephen K. Brannan, MD, and John D. Young were appointed to the company’s Board of Directors. Dr. Brannan has over 25 years of clinical development experience in central nervous system disorders and previously served as Chief Medical Officer of Karuna Therapeutics, the company said. He also held clinical […] The post Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1792533805,
                "headline": "Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors"
              },
              {
                "id": 143032216,
                "url": "https://finnhub.io/api/news?id=5c554f19368c85befd37cd10c9178598e9f34ce0b2fce123c581d489d25d19b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In the latest trading session, Pfizer (PFE) closed at $30.11, marking a +2.28% move from the previous day.",
                "category": "company",
                "datetime": 1792529105,
                "headline": "Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing"
              },
              {
                "id": 143031685,
                "url": "https://finnhub.io/api/news?id=7a8988392bd2d135c2ac2c92d98b1a5b3a99249e4b33855c229ecd63766a3596",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Intel leads today's most-active S&P 500 scan by volume as price moves are mixed and most names trade below their 50-day average volume.",
                "category": "company",
                "datetime": 1792519558,
                "headline": "Most Active S&P 500 Stocks in Today's Session"
              },
              {
                "id": 143030218,
                "url": "https://finnhub.io/api/news?id=e747848b56e46bf9d01a9ff03a13dec6283182b4d2d7bed43caec00c1f2ac2c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna stock is surging ahead of a closely watched cancer data readout in Madrid, and the stakes could not be higher for a company with nearly $800 million in quarterly losses and no approved cancer product yet.",
                "category": "company",
                "datetime": 1792518806,
                "headline": "Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%"
              },
              {
                "id": 143025927,
                "url": "https://finnhub.io/api/news?id=6571c3c98b4a4708822b6076548fb51d5da07a62e9517d2f0621dfd89a165832",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1792497604,
                "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 143022281,
                "url": "https://finnhub.io/api/news?id=50f9b627fa3ce0b22af7021f9aebc3e7da826c78555020e22b24b208e054663b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Two drugs, Mounjaro and Zepbound, accounted for $14.9 billion of Eli Lilly's (LLY) $23.0 billion in revenue during fiscal Q2 2026. This leaves Eli Lilly relying on two medicines for most of its sales at a time when the price it gets for them is falling. So why is so much of Eli Lilly's business running through two drugs.",
                "category": "company",
                "datetime": 1792494177,
                "headline": "Is Eli Lilly Stock Too Dependent On Two Drugs?"
              },
              {
                "id": 143022422,
                "url": "https://finnhub.io/api/news?id=ca468105e31efbb60004e63f76e7f173abf5d343dc507fdf01943ef76470ace5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "RALEIGH, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Slate Medicines, Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache disorders, today announced the appointment of Stephen K. Brannan, MD, and John D. Young to the company’s Board of Directors. Dr. Brannan brings more than 25 years of clinical development experience in CNS disorders",
                "category": "company",
                "datetime": 1792494000,
                "headline": "Slate Medicines Strengthens Board of Directors with Appointment of Stephen K. Brannan, MD, and John D. Young"
              },
              {
                "id": 143021768,
                "url": "https://finnhub.io/api/news?id=828a2ad17368a0f98de3c9e2a32402a0358dfeaae7b14b3313e10efa4e8f913a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Former Pfizer Chief Scientific Officer and President of Worldwide Research, Development and Medical brings deep experience translating scientific innovation into life-changing medicines for patients CAMBRIDGE, United Kingdom, October 20, 2026 – Maxion Therapeutics, a biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein-coupled receptor (GPCR)-driven diseases, today announced the appointment of Mikael Dolsten, MD, PhD, as an independent Non-Executive Dire",
                "category": "company",
                "datetime": 1792486800,
                "headline": "Maxion Therapeutics Appoints Biopharma Leader Mikael Dolsten to Board of Directors"
              },
              {
                "id": 143019784,
                "url": "https://finnhub.io/api/news?id=69346817c85d7e783fed7205b9bf22b6325b328b59223830eb93b55f8fcf83a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer spent 2026 stacking cancer headlines, from fresh breast cancer approvals to a multibillion dollar oncology alliance, even as quarterly profit swung from a US$2,885 million gain to a loss and net margin moved from 19.7% to 1.7% in the red. Investors who held Pfizer from the start of the year saw a 23.0% return, including dividends. If you were weighing a buy on 1 January, what needed to look credible about this reinvention story to take that risk? A Narrative on Simply Wall St is one...",
                "category": "company",
                "datetime": 1792462357,
                "headline": "What Pfizer Bulls Got Right"
              },
              {
                "id": 143011261,
                "url": "https://finnhub.io/api/news?id=77759d1ec4bc5a7bdfa717de130bd443250a2d353c6e10c8bec9c6ce8ff292d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The stock has outperformed the market this year, and it still looks heavily undervalued.",
                "category": "company",
                "datetime": 1792446421,
                "headline": "Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?"
              },
              {
                "id": 143011404,
                "url": "https://finnhub.io/api/news?id=c3d63b9d232f234f9385e0493dc2d662ce90c6de665e88c03712a2d15b6c7669",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the appointment of Geno Germano to its Board of Directors, effective October 19, 2026.",
                "category": "company",
                "datetime": 1792440300,
                "headline": "Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors"
              },
              {
                "id": 143009597,
                "url": "https://finnhub.io/api/news?id=4982dffdeb351849a404906646263fd5d01cb6bb6967bbf33d83da719d37b0ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Soda, toothpaste, phone service, electricity, and prescription drugs all share one trait: people keep buying them when the economy turns ugly. Five companies built their businesses around that reality, and the way they protect their dividends says more than the yield numbers do.",
                "category": "company",
                "datetime": 1792431910,
                "headline": "5 Dividend Stocks for Investors Who Want Income Without the Market’s Wild Swings"
              },
              {
                "id": 143009574,
                "url": "https://finnhub.io/api/news?id=8070bf91d38ecf0cb55fe6c532381fe54aad64d0db7dcf4b2a2b80d46cc14f93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Regeneron Pharmaceuticals (REGN) stock returned 37.9% in the year to October 16, 2026. This easily outpaced the 16.2% gain for the S&P 500 and left investors looking at a higher price. The underlying business has grown faster lately, yet its operating margin has slipped in each of the past three years. If you buy or hold the shares today, what could three more years of owning them make you.",
                "category": "company",
                "datetime": 1792430174,
                "headline": "How Much Upside Is Left In Regeneron Stock?"
              },
              {
                "id": 143009521,
                "url": "https://finnhub.io/api/news?id=e1026ed1b5c5d490d0342961f462869ea7cb8df27b3f53fe7b00306a8d10a369",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Eli Lilly just crushed earnings again and sits within striking distance of its all-time high, but a looming price war with Novo Nordisk and a dangerously concentrated revenue base raise real questions about how long the momentum holds.",
                "category": "company",
                "datetime": 1792427408,
                "headline": "Prediction: Eli Lilly Stock Could Be a Long-Term Winner for Investors"
              },
              {
                "id": 143008509,
                "url": "https://finnhub.io/api/news?id=50d1bc3a8e7cdf3b0ac1a17a125d300d6a61758bbaea06444f06dc022823753d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Investors holding Gilead Sciences (GILD) likely bought into a steady profit engine. The company relies on HIV drugs, led by Biktarvy, to earn money year after year and fund a reliable dividend. Gilead spent the first half of 2026 acquiring other businesses, including Arcellx and Tubulis, before reporting its fiscal second quarter on August 4, 2026. What did those deals do to the profit you were counting on.",
                "category": "company",
                "datetime": 1792424621,
                "headline": "What Has Changed About Owning Gilead Stock?"
              },
              {
                "id": 143008550,
                "url": "https://finnhub.io/api/news?id=d6507f450720b95afb3fdabb41d83382773fd3f19fbe3a66ff90817f8f1432c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline numbers suggest.",
                "category": "company",
                "datetime": 1792422945,
                "headline": "Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow"
              },
              {
                "id": 143025068,
                "url": "https://finnhub.io/api/news?id=159b70a5f67914fa0ee85292af6e9520ee78a9b2019d73ca757c26fe825318dc",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/19/Roche-Logo--Signage-On-The-Facade-Of-Roc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Roche halts German investments as chief Daniel Steiners warns Berlin that statutory drug rebates shatter trust in the market.",
                "category": "company",
                "datetime": 1792417988,
                "headline": "Swiss Pharma Giant Roche Suspends German Capital Commitments Amid Dispute Over Drug Discounts"
              },
              {
                "id": 143029673,
                "url": "https://finnhub.io/api/news?id=da8185da629a06c4073455524b8dc51bd8f843adff1f706c28538c7bcc0d46fd",
                "image": "https://image.cnbcfm.com/api/v1/image/108433447-17924318551792431853-49103445187-1080pnbcnews.jpg?v=1792431855&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "CNBC's Oliver Renick reports on what names have new options trading hours and where money went before the opening bell.",
                "category": "company",
                "datetime": 1792417940,
                "headline": "Options Action: Key names get new options trading hours"
              },
              {
                "id": 143006809,
                "url": "https://finnhub.io/api/news?id=d0de61016f78232a9de4e16d7a1ce2dabc48550be4e5de1cf8fdd23003ed65fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Bristol-Myers Squibb Company (NYSE:BMY) looks cheaper than Pfizer Inc. (NYSE:PFE) on earnings, even though its latest revenue growth was stronger. That sounds like an easy valuation story until the profit figures enter the picture. Bristol Myers reported a 40% rise in second-quarter adjusted earnings per share, while Pfizer’s adjusted earnings were virtually unchanged. But those […]",
                "category": "company",
                "datetime": 1792417157,
                "headline": "Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch"
              },
              {
                "id": 143008554,
                "url": "https://finnhub.io/api/news?id=008230e38a161a74046be81c0613e072673cebd7dc95d506b53860a1629fc0b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's Q3 results will shed light on its non-oncology portfolio, as demand trends, pricing pressure and vaccine sales shape performance across key therapies.",
                "category": "company",
                "datetime": 1792416300,
                "headline": "Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch"
              },
              {
                "id": 143006798,
                "url": "https://finnhub.io/api/news?id=4e9ad059ca8f6c3950c078995610b2ce006907c46d7d448d37e5dfba5190b29d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A yield above 6% looks like a retirement lifeline until the math behind it starts to crack. Five familiar dividend names are flashing the kind of payout warnings that show up quietly in the numbers long before a cut hits your account.",
                "category": "company",
                "datetime": 1792415722,
                "headline": "These 5 Dividend Stocks Look Like Income Bargains. The Math Says Otherwise"
              },
              {
                "id": 143006605,
                "url": "https://finnhub.io/api/news?id=d8336ff84d088f1fee01e07ce68f8bcfd97ec3f72a7cc63f58f1d6840e973601",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Investors are paying a premium for Johnson & Johnson (JNJ) stock. It trades at 29.2 times earnings, compared to 22.9 for the S&P 500. Shareholders paying that premium need to understand exactly what they are buying, and the priorities at the company have changed. A year ago, during the fiscal Q3 2025 call, executives emphasized how the business would maintain growth despite the loss of exclusivity for STELARA, which is the point when rivals can sell copies of a drug. The corporate focus has shif",
                "category": "company",
                "datetime": 1792414556,
                "headline": "Has Johnson & Johnson Stock Become A Different Bet?"
              },
              {
                "id": 143007331,
                "url": "https://finnhub.io/api/news?id=e63346af1266ab5a54cae65363364926762d38f72f0b87a71b3e94bdc4d2d51b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.",
                "category": "company",
                "datetime": 1792414200,
                "headline": "Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?"
              },
              {
                "id": 143006799,
                "url": "https://finnhub.io/api/news?id=b61378c81752f1164fecf5b87467e8384ea053f62541d7259801a445dff0e56b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Most retirees chase yield and end up with dividends that vanish the moment the economy wobbles. These five stocks solve that problem by pairing high payouts with the kind of coverage ratios that let income keep flowing even when markets turn ugly.",
                "category": "company",
                "datetime": 1792413945,
                "headline": "$50,000 in These 5 Dividend Stocks Could Pay You $2,700 a Year"
              },
              {
                "id": 143002988,
                "url": "https://finnhub.io/api/news?id=1354b4b2b6bda26e04876ec271c536c32fcddbfc47b748c1f48b67bf09f4a17b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "New Report puts the global market at $89bn in 2025, with chronic and rare disease, precision medicine and outsourcing to contract researchers driving growth — and IQVIA, ICON, Parexel, Pfizer and Roche among the 20 companies profiledDublin, Oct. 19, 2026 (GLOBE NEWSWIRE) -- \"Clinical Trials Market Size, Share & Trends Analysis Report by Phase, Study Design, Indication, Indication by Study Design, Service, Sponsor, Region, and Growth Forecasts, 2026-2033\" has been added to ResearchAndMarkets.com'",
                "category": "company",
                "datetime": 1792404060,
                "headline": "Global Clinical Trials Market Size, Share, Trends, and Forecast, 2026-2033 | Market to Reach USD 158.4 Billion at 7.7% CAGR as Decentralized Trials and R&D Outsourcing Accelerate"
              },
              {
                "id": 142988608,
                "url": "https://finnhub.io/api/news?id=981c4939bb12dccff9bebb22223c1a799ab1e82b029f1359f5435ffb1584a732",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "It has been a volatile year for the biotech.",
                "category": "company",
                "datetime": 1792349520,
                "headline": "Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?"
              },
              {
                "id": 142987483,
                "url": "https://finnhub.io/api/news?id=42e7d468911e976f80f6212ff5d4374b2d00c1c529f55a2aad659d0fade6032a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "These five high-yield dividend stocks are paying yields of 5.88% to 16.72% -- but beware of a few key risks.",
                "category": "company",
                "datetime": 1792335000,
                "headline": "Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year"
              },
              {
                "id": 142962658,
                "url": "https://finnhub.io/api/news?id=198a6315990d608bfe3725dd1da71c35e788e8162f702a836e622ba94580f1bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key TakeawaysKraft Heinz yields 7. 2%, and Pfizer 6.",
                "category": "company",
                "datetime": 1792253706,
                "headline": "Pfizer or Kraft Heinz: Only One Gets My Dividend Dollars for the Next 10 Years"
              },
              {
                "id": 142957851,
                "url": "https://finnhub.io/api/news?id=7fbbc87921f5eb6aebe1a84de39e7ad8c2e918ec67c718d7d159b99c51415cdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&P 500 over the identical period would have yielded about $11,790. By mid-2026, two drugs, Zepbound and Mounjaro, accounted for most of the company's sales. How early did those two drugs show up in what Lilly said and filed.",
                "category": "company",
                "datetime": 1792205822,
                "headline": "What Was Eli Lilly Telling You Before Its Stock Ran?"
              },
              {
                "id": 142961354,
                "url": "https://finnhub.io/api/news?id=7f53e7e201129acaa174985f4cf5a99b4f5661557e3655f0da6542c22d807f31",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/17/Washington-jan-30-2025-Vice-President-J-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "JD Vance touted TrumpRx and Trump Accounts as key economic wins, highlighting prescription drug savings ahead of the midterm elections.",
                "category": "company",
                "datetime": 1792203743,
                "headline": "JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midterms"
              },
              {
                "id": 142955409,
                "url": "https://finnhub.io/api/news?id=ddb56e3c9661675f49062aebfa86d5d29be9a5e9841df1481875ad51a4717ce5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacing the 1.9% return of the S&P 500. A higher forecast or a climbing share price means little in isolation. When the corporate numbers and the technical chart align, however, the combination warrants closer scrutiny. So how far did management raise its forecast, and why.",
                "category": "company",
                "datetime": 1792198389,
                "headline": "When Amgen's Forecast And Chart Say The Same Thing, Pay Attention"
              },
              {
                "id": 142954216,
                "url": "https://finnhub.io/api/news?id=4ceb14cf168e6a03b7c306392042043ca662a3e864ad75e2c2967d3eb042758f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Gilead Sciences (GILD) built its foundation on HIV treatment. Biktarvy alone accounted for $14.3 billion of the company's $29.4 billion in fiscal 2025 revenue. Yet another segment of the HIV business is growing at a much faster pace, and it targets people who do not currently carry the virus. Gilead expects a regulatory decision regarding a new option in this category in early 2027. So what is that business, and how much is it selling today.",
                "category": "company",
                "datetime": 1792197478,
                "headline": "Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?"
              },
              {
                "id": 142953213,
                "url": "https://finnhub.io/api/news?id=e0d5644bdb1a894b876cd8a527913e2c730f1125e7d0685ae819033f70376096",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to the S&P 500. As the broader market rises and falls each day, the pharmaceutical stock's individual performance blends with the rest of that capital. So when the market drops, does Amgen make your losses bigger.",
                "category": "company",
                "datetime": 1792196033,
                "headline": "Is Amgen Stock Increasing Your Market Risk?"
              },
              {
                "id": 142949994,
                "url": "https://finnhub.io/api/news?id=c04a2244a0a10a4c2d85476e268f0d2dc066fdc841c16620b57e525d6e322ba6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's dividend yield is attractive, but investors need to know if it can maintain it.",
                "category": "company",
                "datetime": 1792177980,
                "headline": "Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?"
              },
              {
                "id": 142959210,
                "url": "https://finnhub.io/api/news?id=b3986a48a3f5afab657ba95ce3d87f80df82d15165f29bb14aad7f91ddb88834",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "S&P 500 most-active stocks for Oct. 16, 2026: SMCI, F, BAC, T, PLTR, NKE, ORCL, HPE, MRNA, and PFE saw heavy volume, with sharp declines and modest gains.",
                "category": "company",
                "datetime": 1792173976,
                "headline": "Most-Active S&P 500 Stocks in Oct. 16, 2026 US Session"
              },
              {
                "id": 142949141,
                "url": "https://finnhub.io/api/news?id=7f878e1d7b8e6ca6594ebcc4d0bd6c82c52bece760c60ab0ea552e559d275df8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a collision course with the drugs Wall Street is betting everything on.",
                "category": "company",
                "datetime": 1792172719,
                "headline": "Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know"
              },
              {
                "id": 142949116,
                "url": "https://finnhub.io/api/news?id=3ef7e3394222e814a77c1b38975d9ebbbf55e72abf7cf7332ad721955ff8675c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth in important parts of their pharmaceutical portfolios. According to Yahoo Finance’s September 23, 2026 valuation snapshot, Pfizer trades at 9.67 times forward earnings, compared with AbbVie’s 16.39 times. That makes Pfizer cheaper on a forward P/E basis, but […]",
                "category": "company",
                "datetime": 1792172610,
                "headline": "Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?"
              },
              {
                "id": 142949190,
                "url": "https://finnhub.io/api/news?id=c959e477e65a218a0cad05f9bd494251447e606cfc31fc5528eee170530d7ad3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial fate is bearing the worst of it. Whether its big-pharma partner can change that story is the question every shareholder now faces.",
                "category": "company",
                "datetime": 1792169050,
                "headline": "Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady"
              },
              {
                "id": 142950896,
                "url": "https://finnhub.io/api/news?id=520998ae67bfdba9099c5ae30f2e78e97d034e9eac14a9babba558891235be0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer will release its third-quarter earnings next month, and analysts anticipate a double-digit profit dip.",
                "category": "company",
                "datetime": 1792164342,
                "headline": "What to Expect From Pfizer's Q3 2026 Earnings Report"
              },
              {
                "id": 142948003,
                "url": "https://finnhub.io/api/news?id=9dbc95242c8d52265d5c0557a75bf5612f2300b046560659575730db61480277",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna stock is shedding 10% after a blistering cancer vaccine run, and the question now is whether profit takers know something the bulls don't ahead of a critical trial readout later this month.",
                "category": "company",
                "datetime": 1792162163,
                "headline": "Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put"
              },
              {
                "id": 142948004,
                "url": "https://finnhub.io/api/news?id=3baf1ee24e890652fecbebc36de430f14066942b4fdd1616633ea9c823267896",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares reached their highest close in a year on October 15, 2026, ending the session at $236.50. Investors paying that premium are betting the drugmaker is ready to grow again. To meet those expectations, its sales, nearly all from COVID vaccines, have to stop shrinking, while its newer vaccines and cancer drugs have to start selling. Has the business caught up with Moderna's share pri",
                "category": "company",
                "datetime": 1792161868,
                "headline": "What Is The Case For Waiting On Moderna Stock?"
              },
              {
                "id": 142930843,
                "url": "https://finnhub.io/api/news?id=429e2a1fa563a7d185d0ec9fa4b1c6774eefa25140f82a3a32e8ccc8285c7ebd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer recently secured expanded FDA approval for TUKYSA as a chemotherapy free maintenance option in HER2 positive metastatic breast cancer and reported a wide slate of infectious disease vaccine data, including late stage Lyme, pneumococcal and RSV studies. The breadth of vaccine and oncology updates points to Pfizer leaning heavily on late stage pipelines and real world evidence to support future portfolio mix as older products face patent expiry and COVID sales pressure. We will now look...",
                "category": "company",
                "datetime": 1792125052,
                "headline": "Tukysa Approval Might Change The Case For Investing In Pfizer Stock (PFE)"
              },
              {
                "id": 142922197,
                "url": "https://finnhub.io/api/news?id=c93cda2ba5d80fdc909491fee9ad005cc47ccd0943ec35f3e56e233bbddf67d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Verizon and Pfizer pay generous dividends, and each has a different path to growth. Here's how income investors can lock in yield before year-end.",
                "category": "company",
                "datetime": 1792096980,
                "headline": "2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends"
              },
              {
                "id": 142922353,
                "url": "https://finnhub.io/api/news?id=2d2ff58faef3e04e177be6aec9db9f4e4425733280d18032d3b23c08e566578f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key TakeawaysPfizer yields 6. 3% and GSK yields 4.",
                "category": "company",
                "datetime": 1792094396,
                "headline": "Better Dividend Stock: Pfizer vs. GSK"
              },
              {
                "id": 142922269,
                "url": "https://finnhub.io/api/news?id=c7865f7724923f82ec5f2ffee87e7389c60a2dc5ec98a0c9ffd0eb37e2d969ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand exactly what they hold, and the drugmaker's priorities have changed. During the fiscal Q4 2024 call in February 2025, executives noted that conditions for the GARDASIL vaccine in China remained challenging. By the August 4, 2026 call, management emphasized something else. So what does management talk up now.",
                "category": "company",
                "datetime": 1792093589,
                "headline": "How Has Merck's Story Changed?"
              },
              {
                "id": 142920417,
                "url": "https://finnhub.io/api/news?id=0fcc6a99bb57e8d09d485a37d2e2d7d64a2221923ab8736bdb870d379724be43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Money is leaving the AI trade and landing in healthcare, but one mRNA name is surging at a pace that leaves its closest peers far behind, and a clinical story from weeks ago may explain why.",
                "category": "company",
                "datetime": 1792083305,
                "headline": "Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher"
              },
              {
                "id": 142919291,
                "url": "https://finnhub.io/api/news?id=9b4dc5f84549fc23cc11e827e82d6faa97d78cdf14ce8f97fa48caaeb3957450",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.",
                "category": "company",
                "datetime": 1792074965,
                "headline": "AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142916968,
                "url": "https://finnhub.io/api/news?id=c672232f64323b461ad93b8e09f73cf097459a27d40f9238ec9a21f5836b394e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Altria's cigarettes kill hundreds of thousands of Americans every year, yet its stock is quietly outperforming the S&P 500 by a wide margin in 2024. The question investors now face says as much about ethics as it does about returns.",
                "category": "company",
                "datetime": 1792072942,
                "headline": "This Company’s Products Kill People, But It Has A 6.2% Yield"
              },
              {
                "id": 142915328,
                "url": "https://finnhub.io/api/news?id=b3a8c83dcbe2957ee2b7ef5bda75d1c593820e341cd92a0184bdff2f60f5c80b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors paying that premium appear to be counting on more growth. The company raised its 2026 guidance on October 13, and Chief Executive Joaquin Duato pointed to one new product as one of its most transformative MedTech innovations. So which product is it.",
                "category": "company",
                "datetime": 1792069769,
                "headline": "Where Could Johnson & Johnson's Next Growth Come From?"
              },
              {
                "id": 142947694,
                "url": "https://finnhub.io/api/news?id=01ba33f70604ee78de84933b718c33d452f57a1b8b7d81a37f22462ce579ffc7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/15/Logo-Pfizer-Inc--Is-An-American-Multinat.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer Inc (NYSE:PFE) shares are climbing Thursday to a new 52-week high as drugmakers rally broadly. The move comes a week after the FDA approved a Tukysa regimen.",
                "category": "company",
                "datetime": 1792065623,
                "headline": "Pfizer Stock Hits 52-Week High: What's Going On?"
              },
              {
                "id": 142916771,
                "url": "https://finnhub.io/api/news?id=5024e7ec675170c0a5a25783ae0feb83a84d769bd02bd60c9b343c091dc26a23",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/15/Franklin---April-21--2024-Pfizer-Site-Ma.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "CNBC Final Trades: Weiss picked 10-year Treasuries, Thomas chose XAR, Firestone favored TMO, and Terranova selected PFE.",
                "category": "company",
                "datetime": 1792050980,
                "headline": "Pfizer, Thermo Fisher Scientific And More: CNBC’s ‘Final Trades’"
              },
              {
                "id": 142896564,
                "url": "https://finnhub.io/api/news?id=704fe4e236b4403de7ca0be3343215911cb4c95daf902cf7ffa7f7d6cd6fa5aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Insider purchases, a multibillion-dollar acquisition and progress in vaccine research helped drive interest.",
                "category": "company",
                "datetime": 1792036063,
                "headline": "Why Did GME, BMBL, PFE Stocks Hit 52-Week Highs Today?"
              },
              {
                "id": 142894617,
                "url": "https://finnhub.io/api/news?id=a15dbaf0ec5913d78ad6dd47f8be522dd0a51efa769661f4a206c2f7086f658e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Over the past month, shares of Liquidia (LQDA) have lost 59%, even as the S&P 500 gained 2.5%. Reuters reported that the stock dropped nearly 50% on September 30 after a federal judge ruled that Yutrepia, Liquidia's inhaled lung drug, infringes a United Therapeutics patent. Liquidia subsequently settled all pending litigation with United Therapeutics on October 13, stating that Yutrepia will remain available to patients with PAH without disruption. If the wider market sells off from here, how mu",
                "category": "company",
                "datetime": 1792028830,
                "headline": "How Much Downside Is Left In Liquidia Stock?"
              },
              {
                "id": 142889244,
                "url": "https://finnhub.io/api/news?id=434733031d20fe4cdc19bc79cf48d12b65f1d04ad018b78d4055f1173b8c98bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying down a balance owed to its partner Sanofi. This obligation reduced the revenue Regeneron reported from the partnership. So what does Regeneron gain now that the balance is paid off.",
                "category": "company",
                "datetime": 1792014348,
                "headline": "What Could Send Regeneron Stock Higher?"
              },
              {
                "id": 142888488,
                "url": "https://finnhub.io/api/news?id=30968c24443e8adac169e6499d5170bb4ec0b066c47f0edd1601090ab47ea410",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The latest trading day saw Pfizer (PFE) settling at $29.21, representing a +2.96% change from its previous close.",
                "category": "company",
                "datetime": 1792010705,
                "headline": "Pfizer (PFE) Gains As Market Dips: What You Should Know"
              },
              {
                "id": 142887524,
                "url": "https://finnhub.io/api/news?id=b8ee77232da86a78183d15a5616a6bb21a5c2408239f1e2c7c4926f0acf76a2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key TakeawaysPfizer yields 6. 3% and General Mills 7.",
                "category": "company",
                "datetime": 1792006478,
                "headline": "Better High-Yield Dividend Stock: Pfizer vs. General Mills"
              },
              {
                "id": 142887525,
                "url": "https://finnhub.io/api/news?id=3ff6d0ac3a491df2b4d918d8a2cc2eb3868a4183edc6b5ff9bf6b746e25d83e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key TakeawaysPfizer yields 6. 3% and British American Tobacco 6.",
                "category": "company",
                "datetime": 1792005919,
                "headline": "Better High-Yield Dividend Stock: Pfizer vs. British American Tobacco"
              },
              {
                "id": 142887404,
                "url": "https://finnhub.io/api/news?id=6749c3c62359b0a0c47f0efb52a4867735713390da08de110f47958dedfd4031",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key TakeawaysPfizer yields 6. 3% and UPS yields 7.",
                "category": "company",
                "datetime": 1792005178,
                "headline": "Better High-Yield Dividend Stock: Pfizer vs. UPS"
              },
              {
                "id": 142887527,
                "url": "https://finnhub.io/api/news?id=6e5fdea3ffe327c06c850de8344a8d4d33f2aaa210032832eb68a935e64746d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key TakeawaysPfizer yields 6. 3% and Healthpeak Properties yields 6.",
                "category": "company",
                "datetime": 1792004518,
                "headline": "Better High-Yield Dividend Stock: Pfizer vs. Healthpeak"
              },
              {
                "id": 142887528,
                "url": "https://finnhub.io/api/news?id=82a75823e061cb1369148e13a89f3b32292e704c410751ce5d0249849e48e8f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key TakeawaysPfizer yields 6. 3% and Edison International yields 6.",
                "category": "company",
                "datetime": 1792003245,
                "headline": "Better High-Yield Dividend Stock: Pfizer vs. Edison International"
              },
              {
                "id": 142887529,
                "url": "https://finnhub.io/api/news?id=adfe62979ba6dfea2ebdafc51506ca7bf6a011ab0d0ccd3f59e0d7f2ea04b9bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key TakeawaysPfizer yields 6. 3% and Clorox yields 6.",
                "category": "company",
                "datetime": 1792002868,
                "headline": "Better High-Yield Dividend Stock: Pfizer vs. Clorox"
              },
              {
                "id": 142886905,
                "url": "https://finnhub.io/api/news?id=4a188658206b81a14d2781a8560ffb791badea88fc7af0c4f67ced56d4798879",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace for the market.",
                "category": "company",
                "datetime": 1792001102,
                "headline": "Most active S&P500 stocks in Wednesday's session"
              },
              {
                "id": 142885916,
                "url": "https://finnhub.io/api/news?id=b622cb959cbffaf6a3f606c989db14bb104d90fd68454f6db70586c3daa7cf5d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1791995703,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 142885324,
                "url": "https://finnhub.io/api/news?id=5a8727f95f7c77544ee1ddca77ed9062f2b1b2b9cefe45a4640186dcf78ab450",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Lyon (France), October 14, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in meetings with institutional investors at upcoming investor conferences in the United States and Europe. In addition to meeting with investors, Valneva will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming catalysts, primarily the regulatory outlook for the Compa",
                "category": "company",
                "datetime": 1791992700,
                "headline": "Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences"
              },
              {
                "id": 142885199,
                "url": "https://finnhub.io/api/news?id=8719c4b8e9632570b216f01e32f4bd5f253af404e968afa86404db29c4b76bf5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.",
                "category": "company",
                "datetime": 1791990840,
                "headline": "Verastem Gets a New CEO, $250M, and a Shot at Another Cancer Drug"
              },
              {
                "id": 142885082,
                "url": "https://finnhub.io/api/news?id=9329147cc20b6fa9758aebec595e343d9235bf53905fd06f47e3c49d6852403f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A reliable payout, a growing cancer treatment lineup, and improving guidance make this drugmaker worth a second look right now.",
                "category": "company",
                "datetime": 1791988500,
                "headline": "Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline"
              },
              {
                "id": 142885190,
                "url": "https://finnhub.io/api/news?id=5313c7c30a68c51cd37b4545c20a44f5d29631bb3b630b7d2eeedfe04a523c7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "FDL has handed retirees growing income and strong returns for nearly two decades, but the fund comes with a concentrated bet and a quarterly payout quirk that can wreck a fixed expense budget if you are not prepared for it.",
                "category": "company",
                "datetime": 1791987161,
                "headline": "Morningstar’s Dividend ETF Is Kind of Perfect for Retirees Right Now"
              },
              {
                "id": 142885296,
                "url": "https://finnhub.io/api/news?id=1ce6cd3560454fdf14b2b9a8de8b2195008543459e0ddea1762635c2191b81f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The capital required to collect over $108,000 a year in dividends without selling a share swings by more than $2 million depending on one decision you make before buying anything.",
                "category": "company",
                "datetime": 1791986664,
                "headline": "How to Build $9,050 a Month in Dividend Income Without Selling a Single Share"
              },
              {
                "id": 142885198,
                "url": "https://finnhub.io/api/news?id=8fe4192fca1e3129d408489e0653fb7f18bb59e735badf4ccd9ef4299f943ff5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-2029.",
                "category": "company",
                "datetime": 1791985560,
                "headline": "Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?"
              },
              {
                "id": 142885171,
                "url": "https://finnhub.io/api/news?id=c9b08647716d071ec6fe0b839a128a131ee7c33e8c360c3b991b6ae616ec8402",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.",
                "category": "company",
                "datetime": 1791984660,
                "headline": "J&J earnings set ‘negative tone’; Shkreli vs. the FTC"
              },
              {
                "id": 142920081,
                "url": "https://finnhub.io/api/news?id=23fab1a99ee8548665e2ee1e0c5506276de75089410bb4618e15ef8b2a4d6712",
                "image": "https://image.cnbcfm.com/api/v1/image/108409633-1791998483220-1791998313-48998176874-hd.jpg?v=1791998484&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "The Investment Committee gives you their top stocks to watch for the second half.",
                "category": "company",
                "datetime": 1791984093,
                "headline": "Final Trades: Thermo Fisher, Pfizer, U.S. 10-year and the XAR"
              },
              {
                "id": 139941991,
                "url": "https://finnhub.io/api/news?id=e755b73b5b151eaeec8c45b37398c4cbc5c66c071f8442462534f1e6d142644c",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1791982844,
                "headline": "Shares of lifesciences and medical equipment stocks are trading higher following strong earnings from Sartorius."
              },
              {
                "id": 142882629,
                "url": "https://finnhub.io/api/news?id=e7ee454d06681d6eed59a914146d59e967214b8f3d686043bbcc75da682651e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The lineup includes ICOTYDE, an oral treatment for plaque psoriasis. The company has yet to disclose sales figures for the medication. How much the drug can ultimately add to J&J remains an open question. Anyone purchasing shares today takes on that unknown before the answer is in.",
                "category": "company",
                "datetime": 1791980295,
                "headline": "The Open Question Under Johnson & Johnson Stock's Price"
              },
              {
                "id": 142882894,
                "url": "https://finnhub.io/api/news?id=e633f7b2e7801b010b80247fca75c4783c93a59b0ea46e22960e73618dd3c6dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BOSTON, October 14, 2026--MindWalk Holdings Corp. (NASDAQ: HYFT) (\"MindWalk\" or the \"Company\"), a Bio-Native AI company, today announced three senior appointments that strengthen its Boston-based development leadership as the Company’s pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director, Antigen Discovery & Protein Engineering, from Arbor Biotechnologies and previously Pfizer. Joanne Lim, PhD, joins as Director, Preclinical Development, from Orum Therapeu",
                "category": "company",
                "datetime": 1791979260,
                "headline": "MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies"
              },
              {
                "id": 142881791,
                "url": "https://finnhub.io/api/news?id=36e483eedc44eaab03d78c5c1b35e05f9ee13e2a96eaca7260ffe32dd0e9e468",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Four of these five large-cap dividend stocks just dropped sharply, pushing their yields above 6%, but a rising yield can signal opportunity or a warning sign depending on what sits beneath the payout.",
                "category": "company",
                "datetime": 1791978648,
                "headline": "5 Large-Cap Giants Paying 5% and Bigger Dividends to Be Bought and Held Forever"
              },
              {
                "id": 142881685,
                "url": "https://finnhub.io/api/news?id=e763de698418aec47744b120467a490b683d9828a9163494ff75c2b553ce7a01",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a warning.",
                "category": "company",
                "datetime": 1791976559,
                "headline": "J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says"
              },
              {
                "id": 142881771,
                "url": "https://finnhub.io/api/news?id=6ccf6d528dd3146319a13cb3036ac47272d8d5b5185fa9327a697824488b6a43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, October 14, 2026--Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the upcoming IDWeek 2026 congress, held in Washington, D.C., from October 21-24, 2026. Data across 12 oral presentations will showcase the Company’s advancements in the prevention and treatment of infectious diseases.",
                "category": "company",
                "datetime": 1791974700,
                "headline": "Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026"
              },
              {
                "id": 142881772,
                "url": "https://finnhub.io/api/news?id=671c9d1870e02b00e72aba19a1cefbc2aa89841531c55bdc8adc214e3abe8e15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets.",
                "category": "company",
                "datetime": 1791967241,
                "headline": "Pfizer partners with Enodia Therapeutics in $500m drug deal"
              },
              {
                "id": 142856069,
                "url": "https://finnhub.io/api/news?id=19ddbf443d05e538002ed8fb8a4b92ac9ed26efb14a4416a1787066e2d586672",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. The company ranks second within this group for both sales growth and operating margin. Its valuation tells a different story. Leaving out Merck and Pfizer, which each reported a loss in at least one of their last four quarters, Amgen has the third highest P/E of the four companies that can be compared. So how far apart are what Amgen delivers and what",
                "category": "company",
                "datetime": 1791935331,
                "headline": "Is Amgen Stock Worth More Than Its Competitors?"
              },
              {
                "id": 142854576,
                "url": "https://finnhub.io/api/news?id=8b6f89cacca838bb479e234a1df8c7e1e8bbc048171fa64e03bd1037650b07d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key TakeawaysPfizer yields 6. 3% and Enbridge 6.",
                "category": "company",
                "datetime": 1791922855,
                "headline": "Pfizer or Enbridge: Only One Gets My Dividend Dollars for the Next 10 Years"
              },
              {
                "id": 142854423,
                "url": "https://finnhub.io/api/news?id=5bc081dc70d815ffa88823067c5acd0248f42961683e09e9d61876123ee214f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market exclusivity. Both drugmakers point to 2028 as the year that matters. Pfizer is acquiring drugs and cutting costs to bridge the gap, while Bristol Myers still relies on Eliquis, an older drug that continues to grow. So what did each company tell investors at its latest report about how that replacement is going.",
                "category": "company",
                "datetime": 1791921571,
                "headline": "What Does Bristol-Myers Squibb Offer That Pfizer Does Not?"
              },
              {
                "id": 142853444,
                "url": "https://finnhub.io/api/news?id=d3c9a96d4f639435dd81c82294ec2c31c03002bcc1a4f295b7f7efba4bcca128",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. Justifying that multiple may require sustained growth, yet most of Lilly's sales still come from the company's two dominant blockbusters, Zepbound and Mounjaro. The pharmaceutical maker has a newer drug on sale and expects to launch it in all major markets worldwide in 2027. So what is the new drug, and is it selling.",
                "category": "company",
                "datetime": 1791919463,
                "headline": "What Is Eli Lilly Stock's Biggest Opportunity?"
              },
              {
                "id": 142853558,
                "url": "https://finnhub.io/api/news?id=b53bb118406cc2186f9f33fe4b6877607b12e96b4dd92d80c6a53091b259f0a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) agreed a research collaboration and licensing deal with Enodia Therapeutics to pursue Sec61-targeting small molecule drugs. Enodia grants Pfizer access to its proprietary Sec61 inhibitor platform, while Pfizer takes charge of clinical, regulatory, and commercial development. The partnership is structured to apply Sec61-directed molecules across multiple disease areas, adding a new discovery track to Pfizer's pipeline. This new Sec61-focused collaboration with Enodia...",
                "category": "company",
                "datetime": 1791918957,
                "headline": "What Is Pfizer (PFE) Really Gaining From Its Sec61 Drug Discovery Deal?"
              },
              {
                "id": 142853559,
                "url": "https://finnhub.io/api/news?id=9f8bf39f52d54e064f117dca0e6a0bed482849e23fd7b09d9c86fdb6c7f9b0d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) closed at $28.40 on October 12. The stock has returned almost 4% during the last six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for State Street SPDR S&P 500 ETF Trust. Pfizer pays a 6% annual dividend yield that most income funds cannot ignore, and […]",
                "category": "company",
                "datetime": 1791918076,
                "headline": "Pfizer (PFE) Pays Out Over 226% of Earnings and Trades at 36.7x Trailing Against 9.8 Forward. What Is the Yield Telling You?"
              },
              {
                "id": 142852544,
                "url": "https://finnhub.io/api/news?id=73fa8a6eebae4badccb7da0734f6771676c136d11fdc2aee574e4b144501db73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Five popular income stocks are flashing warning signs that most yield-chasing investors overlook until after the dividend cut. Here is what the coverage ratios, leverage levels, and share price histories actually reveal about each one.",
                "category": "company",
                "datetime": 1791913558,
                "headline": "Two Mortgage REITs Yield More Than 16%. Their Share Prices Tell Another Story"
              },
              {
                "id": 142852474,
                "url": "https://finnhub.io/api/news?id=288e96a0f39976996dc6855674ee391f80bb8691dcb257d54e15af7043c4f3ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna gains $4.2 billion in a week on cancer-vaccine optimism and Nasdaq-100 inclusion. Can its growth prospects justify its premium valuation?",
                "category": "company",
                "datetime": 1791903660,
                "headline": "MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?"
              },
              {
                "id": 142851332,
                "url": "https://finnhub.io/api/news?id=3f16b6c415c48e8f4a77b7acf9825ed4096b7652f1c18bc42f3f9276c60289bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.",
                "category": "company",
                "datetime": 1791901620,
                "headline": "Reasons Why Investors Should Consider Betting on Arvinas Stock"
              },
              {
                "id": 142848833,
                "url": "https://finnhub.io/api/news?id=206c3c0168651ef247e3abc5c8187db71c74ad011c3d87a833137dcad692d41d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Six high-yield dividend stocks can quietly hand the IRS thousands of dollars every single year, but where you hold them changes everything. The bracket you sit in determines exactly how much you keep or surrender.",
                "category": "company",
                "datetime": 1791898873,
                "headline": "A $750,000 Roth IRA Portfolio Loaded With These Dividend Stocks Pays $47,800 a Year and the IRS Gets None of It"
              },
              {
                "id": 142848861,
                "url": "https://finnhub.io/api/news?id=f40f45fbfb8b715c6acc28c83d077c4986aa1a5aa140fa11f9999f5b7e8bc603",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Six stocks are flashing high yields that look like income bargains, but a closer look at their payout ratios tells a very different story about which ones can actually keep the checks coming.",
                "category": "company",
                "datetime": 1791897328,
                "headline": "These 6 Dividend Stocks Look Like Income Bargains. Their Payout Ratios Say Otherwise"
              },
              {
                "id": 142847559,
                "url": "https://finnhub.io/api/news?id=8e94570cbc97a1189243b8aba385febec5dc7c0cb32879f41c18971c6b6f945e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PARIS, October 13, 2026--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a research collaboration and license agreement with Pfizer Inc. to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of novel small-molecule therapeutics leveraging Enodia’s proprietary platform.",
                "category": "company",
                "datetime": 1791889200,
                "headline": "Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules"
              },
              {
                "id": 142848126,
                "url": "https://finnhub.io/api/news?id=4b9342f81ff4b7efb2202fcc13f5f39cd8d2e4a9ae7477565f61b0f5860f195c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491484031/image_1491484031.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Pfizer is rated a Buy with new and acquired products generated $3.2B in Q2, growing 18% YoY and $13B annualized run-rate. Read more on PFE stock here.",
                "category": "company",
                "datetime": 1791883586,
                "headline": "Pfizer: The Earnings Test That Matters"
              },
              {
                "id": 142882895,
                "url": "https://finnhub.io/api/news?id=46425a9aa7ea873b000e45928355b7054f07a6b195dcf08a7f03fb9cc17773c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A surprise discovery may have saved one of Britain’s oldest chemical companies from sliding into irrelevance.",
                "category": "company",
                "datetime": 1791874800,
                "headline": "‘Ozempic face’ powers revival of a fading British giant"
              },
              {
                "id": 142844367,
                "url": "https://finnhub.io/api/news?id=66560ff9f3f37bf54fdf7009dcfee55437ea1d91b6ce9ebd018012482868e7b8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242072348/image_2242072348.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "From June we saw money rotate out of tech into reflationary sectors, also software, explains Amrita Roy and Uttam Dey. Now, money is moving back into tech.",
                "category": "company",
                "datetime": 1791873000,
                "headline": "S&P Hits All-Time Highs, AI Trade Does All The Work"
              },
              {
                "id": 142824554,
                "url": "https://finnhub.io/api/news?id=44630c809357e2f07010f9d4cdb465c71d19dd1f54e2d65b83653012ff28c8ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna (MRNA) stock has returned 621% over the past twelve months, easily outpacing the S&P 500's 17.0% return. Yet the company's sales have fallen for three consecutive years, and nearly all of that revenue still comes from COVID vaccines. This divergence suggests investors are placing heavy bets on a product Moderna does not sell yet. So what is Moderna getting ready to sell, and how far along is it.",
                "category": "company",
                "datetime": 1791838902,
                "headline": "Where Could Moderna's Next Growth Come From?"
              },
              {
                "id": 142824587,
                "url": "https://finnhub.io/api/news?id=4ada72fac9123a59143a240d812a2ab69d3c89f7ae6796e066c81830e7e4ce67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting for the Phase 1b/2 NX-5948-203 study Earned $27M from Gilead, Pfizer and Sanofi collaborations, including a $10M milestone from Sanofi for first patient dosed in the STAT6 degrader Phase 1 trial Advanced NX-1607 into Phase 1b expansion cohorts in MSS CRC, NSCLC, CRPC and melanoma with",
                "category": "company",
                "datetime": 1791835500,
                "headline": "Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update"
              },
              {
                "id": 142823765,
                "url": "https://finnhub.io/api/news?id=96e15c0ee8d6d0fc2cd258ecd0f9fd393a386da4fa3e0e25243e30ad9a6c7508",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028.",
                "category": "company",
                "datetime": 1791830760,
                "headline": "Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results"
              },
              {
                "id": 142822711,
                "url": "https://finnhub.io/api/news?id=4c955df73a5870ac01a4bfb542467101453f7ed4a3e4ac340997fd39304a05af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.",
                "category": "company",
                "datetime": 1791822002,
                "headline": "Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142821650,
                "url": "https://finnhub.io/api/news?id=5da3845e8880e1b163c09a9039958c5ccb97443572c73a7ab29a55a8ad052c3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Bristol Myers shares surge 35.8% as its Growth Portfolio and pipeline progress fuel momentum, but generic competition and valuation warrant caution.",
                "category": "company",
                "datetime": 1791816480,
                "headline": "BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?"
              },
              {
                "id": 142824596,
                "url": "https://finnhub.io/api/news?id=fab176c327cb9dccc903ff0e731ac2c1189f74af8e844d3a1b549b7443445648",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer is set to cut 330 jobs at its Catania plant as it restructures its business.",
                "category": "company",
                "datetime": 1791816470,
                "headline": "How to Play PFE Stock as Pfizer Cuts 300 Jobs"
              },
              {
                "id": 142821730,
                "url": "https://finnhub.io/api/news?id=dff9a0c97d259797b19fb4e41b1aa26f160d008278d2e20474435162bc6c6088",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028.",
                "category": "company",
                "datetime": 1791814500,
                "headline": "Bristol Myers Stock Is Rising on a Double Dose of Good News"
              },
              {
                "id": 142820026,
                "url": "https://finnhub.io/api/news?id=60a00608051592e1bd42c963200dfe98d0e3d1ff585b7d1b523e74914558da47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Holding high-yield dividend stocks outside a Roth quietly drains thousands of dollars every year, and the losses compound in a way most investors never calculate until it is too late.",
                "category": "company",
                "datetime": 1791813011,
                "headline": "Every Roth IRA Needs These High-Yield Dividend Stocks Over 6%"
              },
              {
                "id": 142820077,
                "url": "https://finnhub.io/api/news?id=83c338dc19e7d70757ae0d10e1dc4e343531b4f837a7c4fd35cb4d713845c54c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Four household names are paying dividend yields above 5%, but their earnings, cash flow, and balance sheets tell a different story than their press releases. Before you count on those checks arriving, there are some serious warning signs worth understanding.",
                "category": "company",
                "datetime": 1791810914,
                "headline": "4 Blue Chip Giants That May Have to Cut Their Dividends"
              },
              {
                "id": 142821608,
                "url": "https://finnhub.io/api/news?id=ea45af680e879736f052cc3e056d4f3d54a04e72978df2b6c3a14f74a948875f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE moves above its 50-day SMA as newer drugs, oncology and obesity treatments fuel growth prospects, but declining COVID sales and patent expirations pose challenges.",
                "category": "company",
                "datetime": 1791809580,
                "headline": "Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock?"
              },
              {
                "id": 142819668,
                "url": "https://finnhub.io/api/news?id=99434cce829fc22f2fec5d8aa6a330985e5f0d6f9f7ce48d33775dc15d6b2ee2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Stephen-King-at-New-York-Comic-Con.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.",
                "category": "company",
                "datetime": 1791781934,
                "headline": "Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'"
              },
              {
                "id": 142810093,
                "url": "https://finnhub.io/api/news?id=98c661ed0ff45874a7168ff5b1c6dc60fcb3a928f3e7f81d04a689c19ab0abc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The ASH meeting runs Dec. 12-Dec. 15 in New Orleans. Sellas is listed at Booth 138, and more than 275 exhibitors are expected.",
                "category": "company",
                "datetime": 1791768132,
                "headline": "SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH"
              },
              {
                "id": 142805666,
                "url": "https://finnhub.io/api/news?id=dbf939503e3ab80b0bba27508c1dd0bc54dbd212134a2f88cf5d79efca6eab28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) has barely rewarded shareholders over the past year. That underperformance has left Pfizer looking inexpensive. Based on the midpoint of the company’s 2026 adjusted diluted EPS guidance range of $2.80 to $3.00, the stock trades at roughly 9.6 times forward adjusted earnings, according to our calculations. There are nine healthcare stocks that […]",
                "category": "company",
                "datetime": 1791723689,
                "headline": "Pfizer Is Trading at Less Than 10 Times Earnings. But Is the Stock Actually Cheap?"
              },
              {
                "id": 142805471,
                "url": "https://finnhub.io/api/news?id=05d0246e23feb6ea04bc875e21de3fc8bd9e69f3b71307b6021029aab29dbc24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Kraft Heinz, Pfizer, Verizon, and Dow all flash yields above 4%, but behind each payout sits a mix of impairments, rising debt, and shrinking sales that could turn a tempting income stream into a costly trap.",
                "category": "company",
                "datetime": 1791723657,
                "headline": "These 4 Dividend Stocks Offer Tempting Yields. But the Warning Signs Are Getting Harder to Ignore"
              },
              {
                "id": 142806035,
                "url": "https://finnhub.io/api/news?id=2fb2b42086031751c87fed45dcdd2e8f905fa6bb37d0d501d511ce8bbee95970",
                "image": "",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1791714900,
                "headline": "Buy 9 S&P500 IDEAL \"Safer\" October Dividend Dogs"
              },
              {
                "id": 142797825,
                "url": "https://finnhub.io/api/news?id=d0e4c844dfa87ed4f53dd4d26660626a03de6fc78fae246c12d12553264f870b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.",
                "category": "company",
                "datetime": 1791686100,
                "headline": "How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?"
              },
              {
                "id": 142794265,
                "url": "https://finnhub.io/api/news?id=20b3ec64a00e8590d74770048a062e3b52c4c2001e38317bd6f31864e59c2ea0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Big Tech is pouring an estimated US$700b into AI infrastructure this year, and healthcare is where that spending will really be tested. Hospitals and drugmakers are under pressure to prove that algorithms can cut costs, reduce burnout, and improve care, not just sound good in pitch decks. This article spotlights three Transformative AI Healthcare screener stocks that show how that shift is already taking shape. The three stocks below are a small sample of what AI in healthcare looks like in...",
                "category": "company",
                "datetime": 1791656049,
                "headline": "Pfizer And 2 Other Top AI Healthcare Stocks"
              },
              {
                "id": 142793598,
                "url": "https://finnhub.io/api/news?id=e2c044a3edad802302c5463361bfdb5979a012f165f167acec0090fcb6fc51bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key Stats for Pfizer StockCurrent Price: $28. 28Target Price (Mid): ~$29Street Target: ~$29Potential Total Return: ~4%Annualized IRR: ~1% / yearWhat Happened?Four Wall Street firms raised their Pfizer (PFE) price targets between October 6 and October 9, and none of them changed its rating.",
                "category": "company",
                "datetime": 1791648400,
                "headline": "Four Analysts Raised Their Pfizer Targets in One Week Without an Upgrade. Here’s Where the Stock Could Go By 2030"
              },
              {
                "id": 142792909,
                "url": "https://finnhub.io/api/news?id=72849dd58b628746f7751b46cb2554c7ebd0f02450f3e12b925fb01281b2eaf8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer has quietly put together a 22.1% one year share price gain, helped by a steady drumbeat of oncology news, and the question for you now is whether that move still lines up with what the business earns. The 22.1% one year return puts more weight on the question of whether Pfizer’s current earnings can support that kind of re-rating in the stock. Fresh approvals such as Tukysa’s expanded use in HER2 positive metastatic breast cancer, alongside a broader oncology pipeline, may support...",
                "category": "company",
                "datetime": 1791641728,
                "headline": "Is Pfizer (PFE) Overvalued Even After Its Oncology Progress?"
              },
              {
                "id": 142791797,
                "url": "https://finnhub.io/api/news?id=97371cf754bec6351a4b79af870a8da732ba9eb407fd85cb89a34a39d5305481",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Six dividend stocks in a $500,000 portfolio sound like a solid income plan, but where you hold them decides how much of that income you actually keep, and the difference compounds into a number most investors never calculate.",
                "category": "company",
                "datetime": 1791640839,
                "headline": "How Much More Dividend Income a Roth IRA Keeps on a Half-Million-Dollar Portfolio"
              },
              {
                "id": 142791143,
                "url": "https://finnhub.io/api/news?id=cb8f75d075716826545a36eb0c4cb1c4d638f20281ad352a52b6f3da268df4bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Retirees chasing income face a choice that looks simple on paper but hides a tax trap, a reinvestment problem, and a dividend cut risk that most income comparisons never mention.",
                "category": "company",
                "datetime": 1791637232,
                "headline": "CDs vs. Dividend Stocks: The Income Gap Could Be Bigger Than Retirees Think"
              },
              {
                "id": 142790289,
                "url": "https://finnhub.io/api/news?id=9d635d8ef3b271a9abb45085bdfba90c4a04689755407997c6a39eb1b4f62fab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A portfolio built entirely around stocks and equity funds can generate $12,300 a month, or $147,600 a year, in income. The no-bond design stands out with the 10-year Treasury yielding 5.2%. Using a blended yield of about 7.4% based on trailing distributions and early October 2026 prices, you’d need roughly $1.99 million to generate the […]",
                "category": "company",
                "datetime": 1791633551,
                "headline": "$12,300 a Month in Dividends and Not One Bond: Is This Portfolio Too Good to Be True?"
              },
              {
                "id": 142772223,
                "url": "https://finnhub.io/api/news?id=d7341b07311e0a7aadb936df0d126442fa321eed83f51e517867f131ac1fb044",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Gilead Sciences (GILD) generated free cash flow equal to 7.1% of its market value over the last twelve months. The median S&P 500 company yielded just 4.5% over the same period. A yield that high means one of two things: the business is either trading at a steep discount, or the market expects it to shrink. So why are investors paying so little for Gilead's cash.",
                "category": "company",
                "datetime": 1791593224,
                "headline": "Why Is Everyone Ignoring Gilead Stock's High Cash Yield?"
              },
              {
                "id": 142769670,
                "url": "https://finnhub.io/api/news?id=9d3295f3bb1adffe88e68237811e5227ae5d48cec72684a1c0f63434b017580a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.",
                "category": "company",
                "datetime": 1791590964,
                "headline": "BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push"
              },
              {
                "id": 142767118,
                "url": "https://finnhub.io/api/news?id=181708a4069b6b1d934b21ddf54a53c5069c5b84640b68e4f23345e8d83044b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "JPMorgan, ASML and Chevron stand out in today's research, with earnings strength, AI-driven demand and record production shaping their investment outlooks.",
                "category": "company",
                "datetime": 1791574740,
                "headline": "Top Research Reports for JPMorgan, ASML & Chevron"
              },
              {
                "id": 142766263,
                "url": "https://finnhub.io/api/news?id=8ec035baab86cf7792f8c473ed9d920f88a6b869215a9474bf070dbaea0125ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Merck (MRK) stock returned 69.6% over the year to October 8, 2026, against 16.3% for the S&P 500. The gain built up over a year of drug approvals and clinical trial results, arriving just as the company prepares for the patent loss on Keytruda, its top-selling drug. So what did Merck show investors over those twelve months.",
                "category": "company",
                "datetime": 1791569538,
                "headline": "Does The Move In Merck Stock Change Anything?"
              },
              {
                "id": 142765273,
                "url": "https://finnhub.io/api/news?id=47173bc504c3fb1af7e77e0a591d37acbd67138829b9392f495a46c5f62f2c37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself.",
                "category": "company",
                "datetime": 1791567949,
                "headline": "Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning"
              },
              {
                "id": 142767147,
                "url": "https://finnhub.io/api/news?id=26ef6d462271e20560d857d34bb2b7d1b91d3c0bed8b86406e36dfb355f69c39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary.",
                "category": "company",
                "datetime": 1791562498,
                "headline": "Moderna stock hits 4-year high on planned national cancer vaccine effort"
              },
              {
                "id": 142765274,
                "url": "https://finnhub.io/api/news?id=b511a432760eaf585dcbace8a10945d149a4dcfeb9e406c5b84325a24f8870a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary.",
                "category": "company",
                "datetime": 1791562498,
                "headline": "Moderna stock jumps on planned national cancer vaccine effort"
              },
              {
                "id": 142764187,
                "url": "https://finnhub.io/api/news?id=548ea96d85965d4231150ac723e0b762e14ae359a530daca3345e608b530e44e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds finish their mechanical purchases and attention shifts back to the pipeline.",
                "category": "company",
                "datetime": 1791560934,
                "headline": "Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up"
              },
              {
                "id": 142792182,
                "url": "https://finnhub.io/api/news?id=d27a1092d3f8ca576571024bb2b791e1e3cce8b13e5eed26a39337bf8b852e1a",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "JP Morgan  analyst Chris Schott   maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $28 to $30.",
                "category": "company",
                "datetime": 1791560192,
                "headline": "JP Morgan Maintains Neutral on Pfizer, Raises Price Target to $30"
              },
              {
                "id": 142764188,
                "url": "https://finnhub.io/api/news?id=c0be8f9acb56797d2b915b09861811e349660a285ed16e2dacad7452b1a0b2ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is up 11.4% year-to-date and leads to a classic value-versus-risk setup. The stock’s forward price-to-earnings multiple appears attractive, along with its healthy operating margin, and strong cash flow generation capacity. However, revenue growth remains sluggish, and the company’s thin bottom-line margin and low return on equity add to investor concerns. It explains […]",
                "category": "company",
                "datetime": 1791559492,
                "headline": "Can Pfizer (PFE) Turn a Forward P/E Discount into Real Returns?"
              },
              {
                "id": 142764190,
                "url": "https://finnhub.io/api/news?id=5303042f76b11e46fe69ae362144922a3b9f39443320de2aceb8efca12f0eca6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.",
                "category": "company",
                "datetime": 1791559080,
                "headline": "FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts"
              },
              {
                "id": 142791501,
                "url": "https://finnhub.io/api/news?id=10b61961f7807912d26796789297a2d0c536581d343ea6718415855d204068b8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/09/Two-Vials-Of-The-Moderna-Vaccine-With-A-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.",
                "category": "company",
                "datetime": 1791558672,
                "headline": "A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally"
              },
              {
                "id": 142764189,
                "url": "https://finnhub.io/api/news?id=5e5e761beb5938e44ca5f23b527254c0189bdfccfe581a0cb4a1e5ec7c5fa50e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer recently received U.S. FDA approval for TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy, expanding its use into the frontline metastatic setting. This decision is important because it moves TUKYSA into an earlier phase of care for a broader patient group, reinforcing Pfizer’s growing emphasis on targeted...",
                "category": "company",
                "datetime": 1791555363,
                "headline": "Frontline TUKYSA Maintenance Approval Could Be A Game Changer For Pfizer (PFE)"
              },
              {
                "id": 142764050,
                "url": "https://finnhub.io/api/news?id=6241482d4670bb6f2d789158b7ebcd3d68f4b48589cd9e9642a3ae4bc086e46c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.",
                "category": "company",
                "datetime": 1791554580,
                "headline": "Cancer Stocks to Consider as Oncology Innovation Accelerates"
              },
              {
                "id": 142764192,
                "url": "https://finnhub.io/api/news?id=02cdd7e218180e1ef8c43c5d4ebf47f999556f4b012901882002fd3f4f5802e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Roche wins FDA approval for Tecentriq in stage III dMMR colon cancer, with trial data showing a 50% lower risk of recurrence or death.",
                "category": "company",
                "datetime": 1791552240,
                "headline": "Roche Gets FDA Approval for Another Label Expansion of Tecentriq"
              },
              {
                "id": 142761581,
                "url": "https://finnhub.io/api/news?id=dac28b3748f2eb337bdde00dc47ba0bedd5c6eea64bc1a19104fa1438a7bf8c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction. The firm's split between Overweight and Neutral ratings reveals a sharp divide in where analysts see real upside and where near-term catalysts could disappoint.",
                "category": "company",
                "datetime": 1791547208,
                "headline": "Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks"
              },
              {
                "id": 142761744,
                "url": "https://finnhub.io/api/news?id=1ed2ca07c5999096b54aa3eda6960a89753276ac08c505d4afde711efa569ef7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
                "category": "company",
                "datetime": 1791547203,
                "headline": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know"
              },
              {
                "id": 142760634,
                "url": "https://finnhub.io/api/news?id=1a5084106507caaec52a9a5a7a3d996225674d910531b6c335c7daf8f20b788b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Four household names are dangling yields above 5% at a moment when their earnings, cash flow, and debt levels raise serious questions about whether those payouts can last. Retirees counting on that income should look carefully before the next dividend announcement.",
                "category": "company",
                "datetime": 1791546059,
                "headline": "4 Household Name Stocks With Dividends in Danger"
              },
              {
                "id": 142763629,
                "url": "https://finnhub.io/api/news?id=878e8a8319515c43d93f8a05679617ac33f23f6ab80e54cd4feeb14c139564e5",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "https://www.nytimes.com/2026/10/09/science/cancer-vaccines-nih-big-bet.html",
                "category": "company",
                "datetime": 1791543602,
                "headline": "Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times"
              },
              {
                "id": 142758965,
                "url": "https://finnhub.io/api/news?id=0da536174a6d05ce0f1a81bbb471d82d66a38669eda3ae33afcdd255a4d34d57",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2244980373/image_2244980373.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Pfizer outlook improves beyond COVID as cost cuts target $2.7B by 2029, though patents and pricing pose risks.",
                "category": "company",
                "datetime": 1791530744,
                "headline": "Pfizer: Previously Bearish, I'm Converting To A Cautious Bull (Rating Upgrade)"
              },
              {
                "id": 142739710,
                "url": "https://finnhub.io/api/news?id=ff2eadf86d47af8338f0f782fe2d50e7e67c0aa90a27adc58e9343384e4eb3d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.",
                "category": "company",
                "datetime": 1791507792,
                "headline": "Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142738442,
                "url": "https://finnhub.io/api/news?id=f75e26b0729c5bff9494c60706fdff46e2e8753e7576109a0837be7c38c177d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) stock has returned 17.5% over the past three months, easily outpacing the 3.7% return for the S&P 500. The board also just declared its 352nd quarterly dividend in a row. That reliable payout may be why many investors hold the shares, yet on Pfizer's latest earnings call, management was asked what it would take to cut that dividend. So what is Pfizer's management preparing for.",
                "category": "company",
                "datetime": 1791506167,
                "headline": "Should You Be Worried About Pfizer Stock?"
              },
              {
                "id": 142736104,
                "url": "https://finnhub.io/api/news?id=bff74f60d6f2160c55eb02e7e452a8c1637af7ee73d80472a98ad1b017bcc0e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Regeneron Pharmaceuticals (REGN) stock currently trades at 17.6 times earnings. That represents a notable discount to the 21.5 multiple of the median S&P 500 company. The shares have lost 4.1% over the past six months, trailing the 15.7% return of the broader index. Over twelve months, however, the stock returned 27% against the index's 17.1%. A valuation this low suggests investors are either overlooking a sound drug maker or pricing in underlying problems. So how healthy is the business you wo",
                "category": "company",
                "datetime": 1791505165,
                "headline": "What Is Going On With Regeneron Stock?"
              },
              {
                "id": 142731116,
                "url": "https://finnhub.io/api/news?id=56c4b9df2d8bb52a98b411bb58b15d604819fb7d63348aee66e63ae86e8939c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.",
                "category": "company",
                "datetime": 1791472740,
                "headline": "NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido"
              },
              {
                "id": 142731117,
                "url": "https://finnhub.io/api/news?id=4717a0779f0ec6bcd4992f6a5f6b0817fb039cf492e7720d9d23290be9516d83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1791472201,
                "headline": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 142731006,
                "url": "https://finnhub.io/api/news?id=5a109b003ce25165ba0d4a6540c1081b50be8c1b4715914995cee70b54b60850",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE's oncology growth in Q3 hinges on key drug sales, biosimilars and progress across a late-stage pipeline.",
                "category": "company",
                "datetime": 1791471960,
                "headline": "Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results"
              },
              {
                "id": 142729927,
                "url": "https://finnhub.io/api/news?id=7698b7b95ae3a302f72e62e7b8383fc656b58d894029684839abc9b3af85888e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's Tukysa combo regimen wins FDA approval for frontline maintenance breast cancer treatment, extending its use beyond the second-line setting.",
                "category": "company",
                "datetime": 1791470700,
                "headline": "FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer"
              },
              {
                "id": 142729928,
                "url": "https://finnhub.io/api/news?id=555bb4ff1a2c4f567c91e6debd300b7636725b08310699c3a9a31a55f09bd064",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) just picked up a fresh U.S. FDA approval for TUKYSA as a chemotherapy free maintenance option in frontline HER2 positive metastatic breast cancer, putting its oncology portfolio back in focus for investors. The fresh TUKYSA approval lands at a time when Pfizer’s share price has climbed 15.5% over the past 90 days and delivered an 11.2% year to date share price return, while the 1 year total shareholder return of 16.7% points to momentum gradually rebuilding after a weaker multi...",
                "category": "company",
                "datetime": 1791468438,
                "headline": "Pfizer (PFE) Could Be 3% Below Fair Value After Fresh TUKYSA FDA Approval"
              },
              {
                "id": 142727185,
                "url": "https://finnhub.io/api/news?id=af927b0037b94c74ca80fab6b0dc7f209a30bc876880f655f7ec6f6a5a778891",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The firm said Pfizer’s near-term performance largely depends on results from the Mevpro-1 trial of Mevrometostat, an experimental prostate cancer drug.",
                "category": "company",
                "datetime": 1791466552,
                "headline": "PFE, LLY, MRK Stocks In Focus: Cantor Raises Price Targets On Pharma Behemoths, But Flags Growth Concerns For Pfizer"
              },
              {
                "id": 142727090,
                "url": "https://finnhub.io/api/news?id=0688d127863f6ca3723014b4be75639b1c3c252c1a66993d6b5a831a7e6f7cb4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.",
                "category": "company",
                "datetime": 1791466500,
                "headline": "Pfizer Trades Under 10 Times Forward Earnings With a Yield Near 6%. Here's What History Says Happens Next."
              },
              {
                "id": 142727471,
                "url": "https://finnhub.io/api/news?id=92d898d7bb0b9399c9aa5f8018e4ae2153db23bb51ab84a342484cc157289358",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Medicus Pharma (NASDAQ:MDCX) is positioning its precision oncology-led pipeline for a series of clinical and regulatory milestones, with partnerships and licensing deals central to the next phase of development, the company said in a shareholder update marking its third anniversary. The...",
                "category": "company",
                "datetime": 1791464640,
                "headline": "Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances"
              },
              {
                "id": 142727204,
                "url": "https://finnhub.io/api/news?id=0777919541fde067a3ae7f2057a4e37174b1a46ec3889aa06a812dc2cfa4d84e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Amgen (AMGN) stock has returned 44% over the past twelve months, easily outpacing the 17.1% gain for the S&P 500. Investors looking at that rally might question what catalysts remain to push shares higher. One candidate is an experimental therapy that is not yet on the market, and executives say its development is progressing rapidly. So what is that drug, and how far along is it.",
                "category": "company",
                "datetime": 1791464604,
                "headline": "What Would It Take For Amgen Stock To Move Higher?"
              },
              {
                "id": 142727426,
                "url": "https://finnhub.io/api/news?id=c75087151ebc2857a0c53827a5539de366cadf0f9752f7034a3a22a181aff118",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "When the paycheck stops at retirement, your portfolio has to carry the weight, and one dividend cut can force painful choices between a tighter budget and selling shares at the worst moment. These five stocks were chosen to avoid exactly that fate.",
                "category": "company",
                "datetime": 1791461740,
                "headline": "Ready to Retire and Want $7,500 a Year in Passive Income? Invest $25,000 in Each of These 5 Dividend Stocks"
              },
              {
                "id": 142727473,
                "url": "https://finnhub.io/api/news?id=4051c93af0ae03f5010c6b5d6ba875ebbbe34165845887c2b6bbf8c2b3ed22ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient DevelopmentPHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today provided a shareholder update celebrating its third anniversary, highlighting three years of progress, focused on execution and capital efficient drug d",
                "category": "company",
                "datetime": 1791460800,
                "headline": "Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value"
              },
              {
                "id": 142724248,
                "url": "https://finnhub.io/api/news?id=52203aa110686a9e40b99c684ab2d4ce268a4ceffc9de4ed7c02f527a1b54468",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's yield towers over Johnson and Johnson's, but a bigger number on paper can hide serious risks underneath. Before you chase that payout, consider what a frozen dividend, rising debt, and a multibillion-dollar write-down actually signal about income reliability.",
                "category": "company",
                "datetime": 1791458114,
                "headline": "Pfizer’s Yield Is Three Times Bigger. Johnson & Johnson’s Dividend Has Something Pfizer Does Not"
              },
              {
                "id": 142727189,
                "url": "https://finnhub.io/api/news?id=760fce1518bbb39e0b14474dc1ed7232e38a2ceb9a2cd815abd69688e7ac31b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "LLY's oncology portfolio is poised for growth as Jaypirca, Inluriyo and Retevmo may offset slower Verzenio sales and mature-drug declines.",
                "category": "company",
                "datetime": 1791457500,
                "headline": "How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?"
              },
              {
                "id": 142723545,
                "url": "https://finnhub.io/api/news?id=e2acdfe44d61f83193c4c45685f8e11307592adbd3b91b78606875a2d8b3f3ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "At Veeva R&D and Quality Summit on October 20-21 in Boston, Veeva Systems (NYSE: VEEV) will bring together leading biopharmas, emerging biotechs, CROs, and sites — including Duke University, Eli Lilly and Company, Pfizer, Sanofi, Tolmar, UCB, and the University of Pennsylvania — to explain how they are driving new ways of working across drug development and quality.",
                "category": "company",
                "datetime": 1791457380,
                "headline": "Veeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and Quality"
              },
              {
                "id": 142729234,
                "url": "https://finnhub.io/api/news?id=fb16b210e33a6856eeb7e8c23c6234c2f2925424a6be91922c8c4ac741e38ac6",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $27 to $28.",
                "category": "company",
                "datetime": 1791441917,
                "headline": "Cantor Fitzgerald Maintains Neutral on Pfizer, Raises Price Target to $28"
              },
              {
                "id": 142728311,
                "url": "https://finnhub.io/api/news?id=ecc3aa24c04827c09154c3a980ae191c65ad0dc3544291e9e7f3ee41b938ea7d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/08/UniQure-N-V.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "PhRMA sued the Trump administration over its Medicare drug pricing rule, arguing CMS exceeded its authority under federal law.",
                "category": "company",
                "datetime": 1791441332,
                "headline": "Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’"
              },
              {
                "id": 142701310,
                "url": "https://finnhub.io/api/news?id=be0a7e3fa760ed5f0a5c52227739c617a8ce6b41a96fbf2c446e8d620797eaa5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Exelixis (EXEL) stock has returned 46% over the past twelve months, compared with 17.8% for the S&P 500. The company has aggressively repurchased its own stock, reducing its total share count by 21% over the last three years. Because fewer shares remain in circulation, each one lays claim to a larger slice of the profit. So how much is that buyback adding to each Exelixis share you own.",
                "category": "company",
                "datetime": 1791414880,
                "headline": "Is Exelixis Stock Engineered To Make You Money?"
              },
              {
                "id": 142701239,
                "url": "https://finnhub.io/api/news?id=8635cf7d37949658b87073da4024db2959c671efc351a6f074c9c352a14846f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The company is entering what could be a particularly challenging period.",
                "category": "company",
                "datetime": 1791411420,
                "headline": "Pfizer Stock: Buy, Sell, or Hold?"
              },
              {
                "id": 142700319,
                "url": "https://finnhub.io/api/news?id=904768d4646b4c625a90536c16f161ffc15968ceead861754922be31faa62b51",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) looks cheap based on its forward P/E, but its earnings outlook helps explain the discount. But unlike Johnson & Johnson or Eli Lilly, Pfizer’s low earnings multiple is not being driven lower by rapid earnings growth. It is expected to rise because earnings are shrinking. Consensus estimates value Pfizer Inc. (NYSE:PFE) at […]",
                "category": "company",
                "datetime": 1791407981,
                "headline": "Pfizer (PFE) Trades Below 10x Earnings. Why Does Johnson & Johnson (JNJ) Command More Than Twice the Multiple?"
              },
              {
                "id": 142700461,
                "url": "https://finnhub.io/api/news?id=c12b8f97a6cf32e6e7ceadfa8c6afb657871b51256876afcd4f67c3fb23c1985",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BioNTech has seen its share price slide over recent years while the business reshapes itself beyond the COVID-19 vaccine boom, which naturally puts the focus back on what investors are paying for its current and potential sales base. With market sentiment shifting around the restructuring of its manufacturing footprint and the oncology pipeline, the live question is how well the present US$95.73 price lines up with the revenue the company is generating and expects to generate. The stock has...",
                "category": "company",
                "datetime": 1791407561,
                "headline": "Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?"
              },
              {
                "id": 142698492,
                "url": "https://finnhub.io/api/news?id=0b246b4888554c1fbd281fd3ed71ee91182275e248aaef5349a07aad90977172",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) raised its revenue guidance in the second quarter of 2026, held its earnings guidance and announced another round of cost cuts. It also reported a loss of $0.04 a share. That split is the story. Pfizer makes prescription medicines and vaccines, including Eliquis, Padcev, Prevnar and Vyndaqel, and sells them to patients, hospitals […]",
                "category": "company",
                "datetime": 1791395343,
                "headline": "Pfizer (PFE) Trades Below Its Own Average Multiple, Is It Cheap for a Reason?"
              },
              {
                "id": 142698348,
                "url": "https://finnhub.io/api/news?id=0488066b399180d0528892e018d49d01525df360795c8bbcfccdd7cdf3f2d269",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 1.6% and the State",
                "category": "company",
                "datetime": 1791395201,
                "headline": "Sector Update: Healthcare Stocks Rise in Afternoon Trading"
              },
              {
                "id": 142698493,
                "url": "https://finnhub.io/api/news?id=812723fb5c2f184e52585202bd32a7761c65c601b1a01c34a87bf2592b20b2ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, October 07, 2026--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expands the use of TUKYSA to frontline, an earlier stage of metastatic disease, offering a new chemotherapy",
                "category": "company",
                "datetime": 1791392220,
                "headline": "Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer"
              },
              {
                "id": 142698403,
                "url": "https://finnhub.io/api/news?id=24cab9c3b44d655fea5e81162fe16de373b29b91fba1401c2a64dc187a69aaff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Eli Lilly (LLY) stock is priced at 38.7 times earnings, compared with 21.5 for the S&P 500. Investors evaluating that valuation should weigh what drives it, especially since the company's priorities have shifted. In late 2024, management opened its earnings call by detailing how many doses of its weight-loss and diabetes drugs it could manufacture. Today, the primary focus has broadened considerably beyond factory output. So what is it.",
                "category": "company",
                "datetime": 1791389636,
                "headline": "Why You Should Think About Eli Lilly Stock Differently Now"
              },
              {
                "id": 142697105,
                "url": "https://finnhub.io/api/news?id=cd905f42a77eb7c2affcf4a90ce8a5f420122dd713663641175fe36b08ae4f3a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "D-Wave is growing revenue at nearly 180% while Rigetti trades at a lower valuation, but both burn cash heavily and face unproven commercial roadmaps.",
                "category": "company",
                "datetime": 1791386882,
                "headline": "D-Wave Quantum vs. Rigetti Computing: Which Cutting Edge Quantum Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142729236,
                "url": "https://finnhub.io/api/news?id=d89fcec57992c04956d53ceef9bf1795606078091aa7980243c4d3133d88a395",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/07/Logo-Pfizer-Inc--Is-An-American-Multinat.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "The FDA approved Pfizer's TUKYSA combination as a front-line maintenance therapy for advanced HER2-positive breast cancer.",
                "category": "company",
                "datetime": 1791384074,
                "headline": "Pfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease"
              },
              {
                "id": 142697234,
                "url": "https://finnhub.io/api/news?id=4339507ac049db1a7c0298c1148c869a9cabbaeeaa3ec6571348f17b64923e37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) reported Phase 3 results for oral LITFULO (ritlecitinib) in nonsegmental vitiligo, showing positive efficacy and safety outcomes. The late stage study found meaningful facial and total body repigmentation in treated patients, alongside a favorable tolerability profile. Pfizer plans to pursue regulatory submissions for LITFULO in vitiligo across multiple regions, as it aims to broaden its immunology portfolio. The Phase 3 LITFULO vitiligo data is important, but it should be...",
                "category": "company",
                "datetime": 1791382200,
                "headline": "Pfizer (PFE) Posted Positive Phase 3 Vitiligo Results For LITFULO"
              },
              {
                "id": 142694800,
                "url": "https://finnhub.io/api/news?id=0cb0291528fabe296f8b55180027c24a21f169e5f2f4c1c38d3f4f06a13e3aea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a MedTech slowdown, and lingering talc litigation raise a real question about whether that streak justifies buying the stock right now.",
                "category": "company",
                "datetime": 1791379822,
                "headline": "Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?"
              },
              {
                "id": 142729237,
                "url": "https://finnhub.io/api/news?id=09217180d04888f9afed624c706620e9175aec68638d36c22629b25972429126",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance optionPfizer Inc. (NYSE:PFE) today",
                "category": "company",
                "datetime": 1791378323,
                "headline": "Pfizer’s TUKYSA Regimen Obtains FDA Approval As Front-Line Maintenance Treatment For HER2+ Metastatic Breast Cancer"
              },
              {
                "id": 142693109,
                "url": "https://finnhub.io/api/news?id=1d727b3edc93880ce20f7f31e1b63bc8e2a5668502b9e1340a7f6a2b4b93f83f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Some of the most recognizable dividend stocks in the market have been paying shareholders with money they do not actually earn, and the accounting trail reveals exactly how far six of them have pushed that math.",
                "category": "company",
                "datetime": 1791371707,
                "headline": "When Dividends Cost More Than Earnings: 6 Stocks in Danger"
              },
              {
                "id": 142688729,
                "url": "https://finnhub.io/api/news?id=6ad194d9d894555ed679f056f1d4b5be3ec783555de7f4c6b464f108206a5242",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 36.4% gain over the past six months, beating the S&P 500 by 18.9 percentage points.",
                "category": "company",
                "datetime": 1791363407,
                "headline": "1 Healthcare Stock with Competitive Advantages and 2 We Find Risky"
              },
              {
                "id": 142669594,
                "url": "https://finnhub.io/api/news?id=92b0bb0c7c777e8591edd7f172cfed5b9a673feb2abaca180a04301207c3904f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced that 21 abstracts from its oncology portfolio will be presented at the European Society for Medical Oncology Congress 2026 (ESMO 2026), taking place October 23–27 in Madrid, Spain. The presentations span prostate, urothelial, gastric/gastroesophageal junction (GEJ), lung and pancreatic cancers, reflecting Astellas' commitment to advancing standards of care and pursuing new scientific approaches designe",
                "category": "company",
                "datetime": 1791329400,
                "headline": "Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026"
              },
              {
                "id": 142668818,
                "url": "https://finnhub.io/api/news?id=f63f0749169ae7ae30a7ec4cf5fb1b30e2114aec83ba9982b7858496e0e0feaa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) was trading at around $27 on October 5, down 1.35% on the day and up 5.18% over twelve months. The shares yield 6.19%. The company paid out 226.32% of its earnings to do it. Those two facts have to be reconciled before anything else about this stock matters. READ ALSO: What is […]",
                "category": "company",
                "datetime": 1791317375,
                "headline": "Is Pfizer (PFE) a Good or Bad Investment at Today’s Price?"
              },
              {
                "id": 142667782,
                "url": "https://finnhub.io/api/news?id=5be42c579586235957ebe3854c6f16f5170e52eeb4ec0992ee781fdb6d35f2b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna stock has turned a handful of patient shareholders into believers, but a gain this size forces a choice that most investors never plan for in advance. The pipeline promise is real, and so is the risk of giving it all back.",
                "category": "company",
                "datetime": 1791313383,
                "headline": "Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?"
              },
              {
                "id": 142666674,
                "url": "https://finnhub.io/api/news?id=0c4a7bb05de5bb5be7e4cf51ffcd5c358bea665c5b24048d350848ac57ef577b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A couple of the stocks on this list pay more than 6% in dividends.",
                "category": "company",
                "datetime": 1791305402,
                "headline": "3 of the Best Dividend Stocks to Buy in October 2026"
              },
              {
                "id": 142667904,
                "url": "https://finnhub.io/api/news?id=a83aaea651b657c3ecdf60984e7097e9cc1703beaa77b846356c44ef1006fa0f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2298029859/image_2298029859.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Vaxcyte stays a Strong Buy after VAX-31 phase 3 OPUS-1 success; broader pneumococcal coverage and 2027 catalysts are ahead. Click for more on PCVX.",
                "category": "company",
                "datetime": 1791302684,
                "headline": "Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027"
              },
              {
                "id": 142665693,
                "url": "https://finnhub.io/api/news?id=6269f2bea8baec5db48921fc0113fe6e796197b632a4784659dc96f9483af9ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Novavax stock slid on Tuesday after a World Health Organization (WHO) spokesperson told reporters that there was a \"low\" risk of a plague epidemic, after a 28-year-old woman who worked in a Russian anti-plague laboratory died last week.",
                "category": "company",
                "datetime": 1791302343,
                "headline": "Novavax, Moderna stocks fall after WHO calls plague risk 'low'"
              },
              {
                "id": 142665542,
                "url": "https://finnhub.io/api/news?id=652de01064e1b48ad113cb16186b0573cc9fcae6ac89cf833807fb80c8c43be9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE vs. JNJ: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1791297606,
                "headline": "PFE vs. JNJ: Which Stock Is the Better Value Option?"
              },
              {
                "id": 142665559,
                "url": "https://finnhub.io/api/news?id=49aeda10a9d9d9da0354aae87a8d7042faf8094af6e532d73f6a352de7e18d7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.",
                "category": "company",
                "datetime": 1791296520,
                "headline": "AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL"
              },
              {
                "id": 142665691,
                "url": "https://finnhub.io/api/news?id=39313d3c47a3a75899edbf94fe4bea1a29d84843833f544ae9747079bddc5755",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, October 06, 2026--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, to holders of the Common Stock of record at the close of business on November 6, 2026.",
                "category": "company",
                "datetime": 1791295200,
                "headline": "Pfizer Declares Fourth-Quarter 2026 Dividend"
              },
              {
                "id": 142663741,
                "url": "https://finnhub.io/api/news?id=631504fc4ba1b24349758aad4495c3d34a2c08ba4b66f10e9572c1680c84e8bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX), since the company’s rally priced a government-purchase scenario that its product line doesn’t address. Novavax stock trades at $12.32, down 2% in morning […]",
                "category": "company",
                "datetime": 1791294963,
                "headline": "Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher"
              },
              {
                "id": 142662987,
                "url": "https://finnhub.io/api/news?id=bac971396bdc677b3a7769ad8cff18fad8e03f7b75d5f59895750484d0ce7dee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "VAX-31 matched or beat Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all measured strains in the OPUS-1 trial",
                "category": "company",
                "datetime": 1791290648,
                "headline": "Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results"
              },
              {
                "id": 142663189,
                "url": "https://finnhub.io/api/news?id=4faa0df7aedfa938ab7c71337b390fd1c2a5366e0a68000ce5065aab3bdb57e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1791290405,
                "headline": "Are Investors Undervaluing Pfizer (PFE) Right Now?"
              },
              {
                "id": 142662034,
                "url": "https://finnhub.io/api/news?id=92baf4e01a6cc114e359c1d9568a4ba6e164aca65b04b08f10ddcb0fb16f8b8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
                "category": "company",
                "datetime": 1791283234,
                "headline": "2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges"
              },
              {
                "id": 142662035,
                "url": "https://finnhub.io/api/news?id=9481b46988e42ac53af13e068b860e18bbfb1c342506a34519b2a1e37d19ba47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key TakeawaysVaxcyte’s VAX-31 matched Pfizer’s Prevnar 20 on all 20 shared serotypes and Merck’s Capvaxive on 17 of 19 in a 4,047-person Phase 3 trial. Prevnar brought in $6.",
                "category": "company",
                "datetime": 1791265085,
                "headline": "Pfizer’s $6.49 Billion Prevnar Franchise Faces a New Challenger"
              },
              {
                "id": 142639122,
                "url": "https://finnhub.io/api/news?id=8bb94847973785e348cffb4f361c861ff94d0eefa8e49ba9d8860012a1bae4fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.",
                "category": "company",
                "datetime": 1791230702,
                "headline": "Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now"
              },
              {
                "id": 142638488,
                "url": "https://finnhub.io/api/news?id=b912328faf2b062f4a6208a16967cb22fa7e13d4e2d406d3f1a441f06bfdc313",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has actually seen in full. What happens when Madrid finally puts the complete data in front of the market?",
                "category": "company",
                "datetime": 1791226022,
                "headline": "Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips"
              },
              {
                "id": 142638489,
                "url": "https://finnhub.io/api/news?id=75b0bd8242f594950d0b5981d4cc6a0d4cecf283f71ac005bb853e91883c8c2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In the OPUS-1 study, Vaxcyte’s VAX-31 matched or beat immune responses from Pfizer’s Prevnar 20 and Merck’s Capvaxive on most strains those vaccines cover.",
                "category": "company",
                "datetime": 1791225445,
                "headline": "PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case"
              },
              {
                "id": 142637796,
                "url": "https://finnhub.io/api/news?id=fc9b3abfa01aa678c25ac5c60cc919be0aa63ebcd06a46aa465cd2f98dd414bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.",
                "category": "company",
                "datetime": 1791219120,
                "headline": "Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck"
              },
              {
                "id": 142636830,
                "url": "https://finnhub.io/api/news?id=fe851ebbde9421b13e2c41dca244f8ddd15ae8509f691c4bfbc273aa263ab46e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.",
                "category": "company",
                "datetime": 1791212940,
                "headline": "Vaxcyte Stock Spikes 35% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck"
              },
              {
                "id": 142664610,
                "url": "https://finnhub.io/api/news?id=b15fabb45d50c11b8c0934588ae546dc6b3ba72739fdb24c144b1abb74070500",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/05/JPMorgan-Faces-Trump-Lawsuit.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Florida files a lawsuit against Pfizer and CEO Albert Bourla over alleged deceptive vaccine marketing and undisclosed health risks.",
                "category": "company",
                "datetime": 1791212152,
                "headline": "Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims"
              },
              {
                "id": 142637759,
                "url": "https://finnhub.io/api/news?id=846adfc70469f764803393e2aeceb13e35f17d89500c612fc1053c5a73e21eb5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "J&J's diversified portfolio, new drug launches and sales growth give it an edge despite Pfizer's cheaper valuation and higher yield.",
                "category": "company",
                "datetime": 1791212100,
                "headline": "Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation"
              },
              {
                "id": 142636833,
                "url": "https://finnhub.io/api/news?id=04ad7948488d41cdc49895e8fe1dac9a9b0585519ec95bcc6771a222157bb5ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key TakeawaysVaxcyte shares are up about 36% after its VAX-31 pneumococcal vaccine met every primary goal in OPUS-1, its pivotal adult Phase 3 trial. VAX-31 cleared a stricter-than-usual bar against Pfizer’s Prevnar 20 on all 20 shared strains, but on only 17 of 19 against Merck’s Capvaxive.",
                "category": "company",
                "datetime": 1791211396,
                "headline": "Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That “Sets a New Benchmark”"
              },
              {
                "id": 142636834,
                "url": "https://finnhub.io/api/news?id=d9cdb4ebfa46d35515eaf043f5ff52014a8cfaf52f65b85f5469c2f7de74a21d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Vaxcyte’s vaccine was pitted against standard-of-care jabs and proved non-inferior on nearly all serotypes.",
                "category": "company",
                "datetime": 1791211159,
                "headline": "Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority"
              },
              {
                "id": 142636835,
                "url": "https://finnhub.io/api/news?id=b69847d67de97721bb469c835a3eb53af7c7d84086b6e2d012983d6e64c7084d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-stage study. The results strengthened expectations that VAX-31 could compete...",
                "category": "company",
                "datetime": 1791210720,
                "headline": "Vaxcyte shares surge on late-stage vaccine trial success"
              },
              {
                "id": 142636798,
                "url": "https://finnhub.io/api/news?id=02b55fb819eac16ad9dadcdcb5f78fd4425f22a5be3f5f3a3aaf11e2f425c375",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "One thing stands out at Eli Lilly (LLY): how many prescriptions are written for Zepbound and Mounjaro, which may be what buyers are betting on. You may think of them as high-priced drugs, but their U.S. prices are now falling. Yet the stock costs 38.2 times earnings, against 21.5 for the S&P 500. That is the tension. So, how much are the two drugs actually selling.",
                "category": "company",
                "datetime": 1791209955,
                "headline": "Has Eli Lilly Stock Peaked?"
              },
              {
                "id": 142636837,
                "url": "https://finnhub.io/api/news?id=fd962f68cae7aa4078ea11a3895e70baf7df37b780aaa3d2254b9a5560db3c32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.",
                "category": "company",
                "datetime": 1791208320,
                "headline": "Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data"
              },
              {
                "id": 142636940,
                "url": "https://finnhub.io/api/news?id=510fb874c9c2cff75b232cbe6ee6ff5d025f79caf3ff8efa57552eba25d2b454",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.",
                "category": "company",
                "datetime": 1791207420,
                "headline": "SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos"
              },
              {
                "id": 142635079,
                "url": "https://finnhub.io/api/news?id=bbd50232421bb8e0197a66b8016f056af60d001a7acb4adc7d6032521fe23ae1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck.",
                "category": "company",
                "datetime": 1791206339,
                "headline": "Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study"
              },
              {
                "id": 142635018,
                "url": "https://finnhub.io/api/news?id=7b958f44eadfb902b355101a14db5ae8da2c37825cb24f4f10c5cfb373ea7fcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend through its transformation.",
                "category": "company",
                "datetime": 1791205457,
                "headline": "Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142636838,
                "url": "https://finnhub.io/api/news?id=44addfb1c4d5eaf25856435029be8695557069d46edca7716c2b738b88372302",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Vaxcyte Inc. (NASDAQ:PCVX) stock is surging on Monday on positive topline results from its pivotal Phase 3 OPUS-1 trial evaluating VAX-31, an investigational 31-valent pneumococcal conjugate vaccine.The trial assessed the safety, tolerability, and immunogenicity of the candidate in adults to prevent invasive pneumococcal disease and pneumococcal pneumonia.These trial findings will form the foundation for an upcoming Biologics License Application submission to the U.S. Food and Drug Administratio",
                "category": "company",
                "datetime": 1791204917,
                "headline": "Vaxcyte Stock Hits New 52-Week High - Here’s Why"
              },
              {
                "id": 142635030,
                "url": "https://finnhub.io/api/news?id=7838b04318f21aef8b84114465805015970f8ec7b7895a8f99c98a04afd0ed57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Clinical Trials Arena brings you the highlights from EADV 2026, covering key eczema and psoriasis readouts from notable biotech and pharma players.",
                "category": "company",
                "datetime": 1791201446,
                "headline": "EADV26: Key late-stage readouts from the conference"
              },
              {
                "id": 142634275,
                "url": "https://finnhub.io/api/news?id=79e8a4a1c0aeae961e7785bb87893534635e3e9d7ea15bb2d19eaa65fabaa588",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that could reshape the obesity drug race.",
                "category": "company",
                "datetime": 1791198942,
                "headline": "Pfizer’s Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside"
              },
              {
                "id": 142632090,
                "url": "https://finnhub.io/api/news?id=783a9185305730d448c3e142ee23ac4d2f80eaef0717e43318b5e6b32fe2c8b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Put your money to work generating dividend income with these stocks.",
                "category": "company",
                "datetime": 1791191040,
                "headline": "Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income."
              },
              {
                "id": 142625635,
                "url": "https://finnhub.io/api/news?id=f05cbd0e70f3fe7b8bb214cdf07615812097ac6e7396c3fe3f63e14d210432e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.",
                "category": "company",
                "datetime": 1791149700,
                "headline": "Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?"
              },
              {
                "id": 142624637,
                "url": "https://finnhub.io/api/news?id=69e46293fa3cb0d1ab3cc9be8a9da6788e5458a715d05f7bb99c69cedb416105",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Three struggling companies keep sending dividend checks while investors wait for their repairs to kick in, but only one of them has a yield that cash flow actually supports without a fight.",
                "category": "company",
                "datetime": 1791130527,
                "headline": "Pay Me While I Wait: 3 Turnaround Stocks That Keep Paying Investors Through the Rebuild"
              },
              {
                "id": 142624128,
                "url": "https://finnhub.io/api/news?id=c219c8b82db7e2ac7ff2884194258eeb27d6a3de8a8a4544304ce068e9770189",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The crowd is looking at the next couple of years. It should be looking five years into the future.",
                "category": "company",
                "datetime": 1791123600,
                "headline": "Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield"
              },
              {
                "id": 142623564,
                "url": "https://finnhub.io/api/news?id=0239c0fdaed29155b6cf30b792945e313c370a2fe0edfe251cd76905a7b7f109",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2270977838/image_2270977838.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "BioNTech pivots from Covid windfall to oncology with 33 trials and $19B cash; key pumitamig data post-2028. Click for more on BNTX stock.",
                "category": "company",
                "datetime": 1791107051,
                "headline": "BioNTech SE: Moving Past Covid"
              },
              {
                "id": 142624150,
                "url": "https://finnhub.io/api/news?id=7e2cb675536c0c9b14dc0f8ac39311049b0a11e1b60c46a7ab6ab60875ed1795",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.",
                "category": "company",
                "datetime": 1791038700,
                "headline": "3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note"
              },
              {
                "id": 142594447,
                "url": "https://finnhub.io/api/news?id=d1d21206255141734195c124008e63f6b1eccda57d00bf86ab848cb956350bb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Runaway demand for AI data centers, highlighted by Nvidia’s US$5.7t market cap milestone, shows how quickly capital is chasing tools that can crunch medical data, scan images, and support virtual care at global scale. That same engine is starting to reshape healthcare. Missing the early phase may mean missing where a lot of value could potentially accrue. This article breaks down three AI healthcare stocks from the screener that are worth watching. The three stocks covered below are only a...",
                "category": "company",
                "datetime": 1790982394,
                "headline": "3 AI Healthcare Stocks With Earnings Growth Up To 15%"
              },
              {
                "id": 142591927,
                "url": "https://finnhub.io/api/news?id=99f2a0958840d23906a7c13cc2f1b25e3a1e4b5e4ffefc216102db8af91f8298",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.",
                "category": "company",
                "datetime": 1790958901,
                "headline": "Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142590893,
                "url": "https://finnhub.io/api/news?id=61ea93e04e6931a968149d80f6c6599c49c10f7644e3bdad87e1c54aa712cb5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Key Stats for Pfizer StockCurrent Price: $28. 12Street Target (Mean): ~$29Next Earnings: November 3, 2026What Happened?Florida’s attorney general sued Pfizer (PFE:NYSE) and CEO Albert Bourla on Thursday, October 1, alleging the company misled consumers about its COVID-19 vaccine.",
                "category": "company",
                "datetime": 1790955440,
                "headline": "Pfizer’s Eczema Drug Hit a 61% Response Rate the Day Florida Sued. Here’s What It Means for the Stock"
              },
              {
                "id": 142590894,
                "url": "https://finnhub.io/api/news?id=cb965ca3fcf7c506c65490711eaf4e0276641cb84d9c8cca426f1865ba336990",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, October 02, 2026--Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent.",
                "category": "company",
                "datetime": 1790954100,
                "headline": "Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo"
              },
              {
                "id": 142613983,
                "url": "https://finnhub.io/api/news?id=86cc3684902b2709d5ae46550ca0b0dec5b78b110a80fadac5917938042b7661",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent.In the two",
                "category": "company",
                "datetime": 1790939937,
                "headline": "Pfizer Announces Its Two Phase 3 Studies Of LITFULO Demonstrate TRANQUILLO 2 and TRANQUILLO, LITFULO Enhance Facial, Total Body Repigmentation Compared To Placebo; Co. Plans To File Data to Regulatory Authorities Globally, Include FDA And European Medicines Agency"
              },
              {
                "id": 142585466,
                "url": "https://finnhub.io/api/news?id=67bda7f26ae04d0d3f35078b1e3e515457b65d707cb614ee0369159ab7b04c5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.",
                "category": "company",
                "datetime": 1790936840,
                "headline": "How Has Pfizer's Story Changed?"
              },
              {
                "id": 142579893,
                "url": "https://finnhub.io/api/news?id=30e3dd2662713545406c4b67aa92215d1ae10a14ed24338f3927b64ab2729f6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer has been going through a period of transition.",
                "category": "company",
                "datetime": 1790929380,
                "headline": "Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk."
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 247,
            "discarded_article_count": 222
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 22.2,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日3日)；站上MA50；升放量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 31425290,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 27565750,
              "avg_vol_20": 29676715,
              "avg_vol_30": 31425290,
              "range_pct_10": 0.09490509174475224,
              "range_pct_20": 0.11055610687458853,
              "range_pct_30": 0.11055610687458853,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8771836314000603,
              "dist_to_20d_high": 0.013469086727989575,
              "down_shrink_days": 3,
              "breakout_level_20d": 30.44,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.8584337349397594
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 1.9217448577507539,
              "turnoverUsdM": 884.803949464,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1.2
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.PFE",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 28.8758,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2.5,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 3.8,
            "take_profit_price": 31.5315,
            "target_multiplier": 1.9,
            "technical_strength": 1.83,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.3009011003292323,
          "stopLossPercent": 3.8434897155015078,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.PFE",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 0.5771,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 8,
      "atr_pct": 1.92
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 110.79
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.091
    },
    "kdj": {
      "d": 84.78,
      "j": 92.58,
      "k": 87.38,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 61.81
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 494438300,
      "recentSlope": 6470740,
      "previousSlope": -7951380
    },
    "rsi": 78.35,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 28.0135,
      "position": "SAR喺價下",
      "distancePct": 6.71,
      "previousTrend": "上升"
    },
    "ma50": 28.2952,
    "macd": {
      "macd": 0.5890910118754107,
      "trend": "強烈看漲",
      "signal": 0.42558963791787885,
      "histogram": 0.16350137395753184
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 28.735,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 11
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.99,
      "score": 4,
      "avgVolume": 29762155,
      "currentVolume": 29464000
    },
    "derived": {
      "ma20": 28.787,
      "ma50": 28.2952,
      "prevClose": 30.42,
      "avgVolume10": 28191740,
      "avgVolume20": 29762155,
      "changePercent": -1.28,
      "avgVolumeForScore": 29762155
    },
    "ma_cross": {
      "ma20": 28.787,
      "ma50": 28.2952,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 28.719,
      "prevMa50": 28.2306,
      "spreadPct": 1.74,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 27.0015,
      "upper": 30.5725,
      "position": "上半部"
    },
    "rsi_short": 63.59,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.99
    }
  }
}

{
  "close": 30.03,
  "volume": 29464000,
  "changePercent": -1.28
}